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To identify which non-antibiotic strategies could reduce the risk of infectious complications 47 
following prostate biopsy. 48 
 49 
Materials and Methods 50 
We performed a literature search on MEDLINE, Embase, and Cochrane Database for 51 
randomized controlled trials (RCTs) (Inception to May 2020) assessing non-antibiotic 52 
interventions in prostate biopsy. Primary outcome was pooled infectious complications (fever, 53 
sepsis and symptomatic UTI) and secondary outcome was hospitalization. Cochrane risk of bias 54 
tool and GRADE approach were used to assess the bias and the certainty of evidence. Protocol 55 
was registered with PROSPERO (CRD42015026354).  56 
 57 
Results 58 
90 RCTs (16,941 participants) were included in the analysis with 83 RCTs being categorized 59 
into one of ten different interventions. Transperineal biopsy was associated with significantly 60 
reduced infectious complications as compared to transrectal biopsy (RR 0·55, 95% CI 0·33-61 
0·92, p=0·02, I²=0%, participants=1330, studies=7). Rectal preparation with povidone-iodine 62 
was also shown to reduce infectious complications (RR 0·50, 95% CI 0·38-0·65, p<0·000001, 63 
I²=27%, participants=1686, studies=8) as well as hospitalization (RR 0·38, 95% CI 0·21-0·69, 64 
p=0·002, I²=0%, participants=620; studies=4). We found no difference in infectious 65 
complications/hospitalization for six other interventions: number of biopsy cores, periprostatic 66 
nerve block (PPNB), number of injections for PPNB, needle guide type, needle type, and rectal 67 
preparation with enema. In two interventions (needle diameter, rectal preparation with 68 
chlorhexidine) meta-analysis was not possible. Finally, seven studies had unique interventions. 69 
The certainty of evidence was rated as low/very low for all interventions. 70 
 71 
Conclusions 72 
Transperineal biopsy significantly reduces infectious complications compared to transrectal 73 
biopsy and should therefore be preferred. If transrectal biopsy is performed, rectal preparation 74 
with povidone-iodine is highly recommended. The other investigated non-antibiotic strategies 75 





In 2019 more than 190,000 new cases of prostate cancer (PCa) are diagnosed in the USA 79 
causing more than 33,000 deaths1. Worldwide prostate cancer accounts for a significant 80 
proportion of male cancer and mortality. PCa diagnosis is based on biopsies following patient 81 
evaluation for an elevated PSA or abnormal digital rectal examination and there is an increasing 82 
role for pre-biopsy MRI.2,3 Prostatic biopsy remains the keystone for diagnosis and 83 
management of PCa and the most commonly performed diagnostic procedure in urology with 84 
more than 2 million per year.4 Therefore, many efforts have been made to prevent infectious 85 
complications which account for the major adverse events with up to 7% of infections and 3.1% 86 
of sepsis depending of antibiotic prophylaxis regimens.3 Even if an antibiotic prophylaxis is 87 
recommended by every guideline, the incidence of infectious complications is not negligible 88 
and its prevention of utmost importance.2,3 In addition, both the induction of resistance through 89 
the use of antibiotics and side effects must be considered.5 Post-biopsy infections have been 90 
increasing over the last few years.6,7 Thus, antibiotic interventions such as targeted antibiotic 91 
prophylaxis based on rectal swab culture as well as augmented antibiotic prophylaxis applying 92 
more than one antibiotic were introduced to reduce infectious complications.8,9 In a 93 
comprehensive meta-analysis we have recently compiled the evidence of various interventions 94 
for antibiotic prophylaxis.10 In addition to antibiotics different aspects and modalities of biopsy 95 
techniques have been investigated with a view to minimizing adverse events. Among them, 96 
biopsy route, enema, and number of cores have been already suggested as potential factors to 97 
reduce the infectious risk.11,12 Nevertheless, no systematic analysis is available evaluating 98 
various technical aspects of prostate biopsy for reducing post-biopsy infections. 99 
The aim of our comprehensive systematic review and meta-analysis was to investigate whether 100 
and to what extent any non-antibiotic interventions reduce the risk of infectious complications 101 
following prostate biopsy.  102 
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Materials and Methods 103 
 104 
Evidence acquisition 105 
We followed the PRISMA guidance and the Cochrane Handbook for systematic reviews of 106 
interventions.13,14 The protocol was registered at PROSPERO (CRD42015026354). The 107 
detailed PICO (Population, Intervention, Comparison and Outcomes) is provided in 108 
supplementary appendix 1.  109 
 110 
Literature search 111 
The Medline, Embase, LILACS, CENTRAL, Cochrane Database of Systematic reviews 112 
databases and clinicaltrial.gov were searched for randomized controlled trials (RCTs) (last 113 
search 27th May 2020). The grey literature was searched through opengrey.eu and oclc.org. 114 
Potentially-eligible trials were also identified by searching the reference lists of trials, reviews, 115 
and health technology assessment reports (Y.Y). There were no date or language restrictions. 116 
In order to avoid publication bias, abstracts characterized as RCTs, but for which published 117 
manuscripts were not yet available, were included in this systematic review with meta-analysis, 118 
as were funnel plots for interventions involving more than 10 studies. The search strategy is 119 
included in supplementary appendix 2. 120 
 121 
Types of outcome measures 122 
Primary outcome: 123 
x Pooled infectious complications (calculated by summing all types of infectious 124 
complications reported i.e. fever, sepsis, symptomatic UTI). This approach was chosen 125 
since in many studies investigating post-biopsy complications, a distinction between 126 
severe infections (e.g. sepsis) and mild infections (e.g. cystitis) is not reported in detail 127 
(supplementary table 1). 128 
Secondary outcome: 129 
x Hospitalization due to infectious complications.  130 
 131 
Data collection and analysis 132 
Abstract screening, full-text screening, and data extraction was independently performed by 133 
two reviewers (A.P., B.P., or R.V.). For each disagreement, another reviewer (M.I.O., S.M.) 134 
was consulted. All the study authors were contacted to provide missing information if 135 
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necessary. Eight non-English articles were evaluated in the corresponding languages by 136 
members of the author team with appropriate language skills (4×Chinese: Y.Y., 1×French: B.P., 137 
F.B., 1×Spanish: A.P., B.P., 2×Turkish: Mete Cek, former EAU Guideline panel member). One 138 
Japanese article and two Korean articles were translated into English by professional 139 
translators. Among the 90 RCTs there are also eight studies that have so far only been published 140 
as abstracts. The risk of bias (RoB) was independently assessed by two reviewers (R.V., K.D.), 141 
by using the Cochrane RoB assessment tool.14,15 Any disagreements were resolved via 142 
discussion or consultation with another reviewer (M.I.O., S.M.). The GRADE approach was 143 
used to assess the certainty of evidence for each comparison (M.I.O., S.M.).14 144 
 145 
Statistical analysis 146 
The meta-analysis was performed using Review Manager (RevMan) version 5.3. A fixed-147 
effects model was used to calculate pooled estimates of treatment effects across similar studies 148 
and their 95% confidence intervals (CIs). We used risk ratio (RR) for dichotomous outcomes. 149 
We identified heterogeneity by visually inspecting forest plots and using a standard x2 test with 150 
a significance level of α=0.1. We also considered the I2 statistic, which quantifies inconsistency 151 
across trials to assess the impact of heterogeneity on the meta-analysis. Where there was 152 
evidence of heterogeneity, we attempted to determine possible reasons by examining individual 153 




Literature search and characteristics of the included studies 158 
We identified 3111 citations, of those 284 were selected for full-text screening. Reasons for 159 
exclusion are provided in supplementary table 2. A total of 90 RCTs were included in the SR 160 
(supplementary appendix 3). The inclusion process is graphically illustrated in a PRISMA 161 
diagram (figure 1). For all included studies we provide detailed study characteristics in 162 
supplementary table 3. Of the 90 RCTs 83 studies could be categorized into one of ten different 163 
interventions, while 7 studies had unique interventions. Sensitivity analyses for the individual 164 
interventions showed that no changes occurred with or without the data of the eight included 165 
abstracts, which have not yet been published as full-text. 166 
 167 
Risk of Bias (RoB) assessment 168 
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The RoB assessment is graphically illustrated in figure 2.  It is noticeable that the majority of 169 
studies have an unclear RoB regarding random sequence generation, allocation concealment 170 
and blinding of outcome assessment. Furthermore, most studies have been conducted without 171 
blinding patients or personnel, which is certainly also due to the type of technical intervention. 172 
A funnel plot from the interventions with more than 10 studies (PPNB) showed no asymmetry 173 
(details in supplementary appendix 4). 174 
 175 
Study heterogeneity 176 
The I² statistic was 0% in all cases except Intervention 8 (povidone-iodine) where it was 27%. 177 
Since the p-values changed only marginally when using random-effect models for all 178 
interventions and endpoints, we used fixed-effect models throughout. 179 
 180 
GRADE 181 
The certainty of evidence was mainly downgraded due to study design, imprecision and risk of 182 
bias (details in supplementary appendix 5). 183 
 184 
Intervention 1: Impact of biopsy route  185 
 186 
A total of seven RCTs including 1330 patients compared the impact of biopsy route on 187 
infectious complications (supplementary appendix 3). There were significantly lower infectious 188 
complications when the transperineal route was performed (22 events among 673 men) 189 
compared to the transrectal route (37 events among 657 men) (RR 0.55, 95 CI: 0.33 to 0.92; 190 
participants=1330; studies=7; I²=0%; low certainty; figure 3).  191 
Data on hospitalization were reported in three studies with a total of 685 patients. While two 192 
hospitalizations were necessary in 346 patients in the transperineal group, hospitalization was 193 
reported in six cases out of 339 patients undergoing transrectal biopsy without any statistical 194 
difference (RR 0.38, 95 CI: 0.09 to 1.61; participants=685; studies=3; I²=0%; very low 195 
certainty; supplementary figure 1). 196 
 197 
Intervention 2: Impact of number of biopsy cores 198 
 199 
The impact of the number of cores was evaluated in 11 studies including 2626 men undergoing 200 
prostate biopsy (supplementary appendix 3). While ten studies performed transrectal biopsy 201 
one study used the transperineal approach. MA showed 38 infectious complications in 1320 202 
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men randomized to standard and 47 in those 1306 randomized to extended number of cores. 203 
The comparison was not significant (RR 0.80, 95% CI: 0.53 to 1.22; participants=2230; 204 
studies=9; I²=0%; low certainty; figure 4).  205 
Of those studies, only five studies presented data on hospitalization following prostate biopsy. 206 
There was one case of hospitalization among 415 men in the standard group, while four cases 207 
occurred among 411 men in the extended biopsy scheme group. The comparison was not 208 
significant (RR 0.34, 95% CI: 0.05 to 2.13; participants=306; studies=2; I²=0%; very low 209 
certainty; supplementary figure 2). 210 
 211 
Intervention 3: Impact of periprostatic nerve block 212 
 213 
Pain after periprostatic nerve block (PPNB) during biopsy was evaluated in 41 RCTs and 214 
infectious outcomes were reported in a total of 5540 men (supplementary appendix 3). There 215 
were 61 infectious complications among 2633 patients randomized to periprostatic nerve block 216 
and 73 among 2907 patients randomized to no nerve block/control. The comparison was not 217 
significant (RR 1.07, 95% CI: 0.77 to 1.48; participants=3857; studies=26; I²=0%; very low 218 
certainty; figure 5). 219 
Among these studies, only 14 reported hospitalization with 13 cases of hospitalization among 220 
971 men in the PPNB group, while 15 cases occurred among 1128 men in the group without 221 
PPNB. The comparison was not significant (RR 1.13, 95% CI: 0.59 to 2.16; participants=1469; 222 
studies=9; I²=0%; very low certainty; supplementary figure 3). 223 
 224 
Intervention 4: Impact of number of injections for periprostatic nerve block 225 
 226 
Six studies compared the number of injections applied for PPNB and assessed post-biopsy 227 
infections (supplementary appendix 3). MA showed five infections among 459 men 228 
randomized to standard number of injections and four among 468 men randomized to extended 229 
PPNB. The difference was not statistically significant (RR 1.30, 95 CI: 0.35 to 4.76; 230 
participants=478; studies=3; I²=0%; low certainty; supplementary figure 4). 231 
Two studies reported hospitalization with two patients being hospitalized among 147 men 232 
randomized to standard PPNB and two men among 153 randomized to extended PPNB. The 233 
difference was not statistically significant (RR 1.05, 95 CI: 0.15 to 7.32; participants=300; 234 




Intervention 5: Impact of disposable needle guides 237 
 238 
Two RCTs evaluated the use of disposable needle guides compared to reusable guides in a total 239 
of 253 patients (supplementary appendix 3).  240 
There were nine events among 113 men randomized to disposable needle guides and 22 events 241 
among 140 men randomized to reusable needle guides. The difference was not statistically 242 
significant (RR 0.51, 95% CI: 0.24 to 1.06; participants=253; studies=2; I²=0%; very low 243 
certainty; supplementary figure 6). 244 
Both studies evaluated the impact on hospitalization. While four events occurred in 113 men 245 
randomized to the disposable needle guide group, nine events were recorded in 140 men of the 246 
reusable needle guide group. The difference was not statistically significant (RR 0.55, 95% CI: 247 
0.17 to 1.74; participants=253; studies=2; I²=0%; very low certainty; supplementary figure 7). 248 
 249 
Intervention 6: Impact of needle type 250 
 251 
Only two studies investigated the impact of a coaxial needle versus a non-coaxial needle and 252 
reported on infectious complications (supplementary appendix 3). Data analysis revealed no 253 
infections in 171 men in the coaxial needle arm, while one case occurred among 171 men in 254 
the group randomized to the non-coaxial biopsy needles. MA was not possible, because of zero 255 
events in one study. Hospitalization was reported in only one of the two studies and did not 256 
occur in any among the 240 patients.  257 
 258 
Intervention 7: Impact of needle diameter 259 
 260 
The impact of needle diameter was investigated in two studies (supplementary appendix 3). 261 
Data analysis revealed no infections in 133 men randomized to the smaller needle diameter, 262 
while one case occurred among 163 men in the group randomized to the larger needle diameter. 263 
MA was not possible, because of zero events in one study. Hospitalization was not reported as 264 
an endpoint in any study. 265 
 266 
Intervention 8: Impact of rectal preparation with enema 267 
Four RCTs evaluated rectal preparation with enema (supplementary appendix 3). Among 336 268 
men randomized to enema 30 events were recorded, while among 335 men in control group 31 269 
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events were reported. The difference was not statistically significant (RR 0.96, 95% CI: 0.60 to 270 
1.53; participants=671; studies=4; I²=0%; low certainty; figure 6). 271 
Only two studies with each 231 patients per group reported on hospitalization with nine events 272 
in the enema and eight events in the control group. This comparison was not statistically 273 
significant (RR 1.13, 95% CI: 0.44 to 2.86; participants=462; studies=2; I²=0%; low certainty; 274 
supplementary figure 8). 275 
 276 
Intervention 9: Impact of rectal preparation with chlorhexidine 277 
 278 
Two studies investigated the influence of rectal preparation with chlorhexidine (supplementary 279 
appendix 3). Although both studies report infectious complications separately for the 280 
intervention and control groups, the primary outcome cannot be meta-analyzed due to a possible 281 
double case count in one of the studies. 282 
 283 
Intervention 10: Impact of rectal preparation with povidone-iodine 284 
 285 
Nine studies evaluated the use of rectal preparation with povidone-iodine (supplementary 286 
appendix 3) in a total of 1936 patients. MA showed 61 infections among 930 men in the 287 
povidone-iodine group and 131 among 1006 in the control group. The difference was 288 
statistically significant (RR 0.50, 95% CI: 0.38 to 0.65; participants=1686; studies=8; I²=27%; 289 
low certainty; figure 7).  290 
 291 
Four studies reported on hospitalization with a total of 12 men hospitalized among 285 men 292 
randomized to povidone iodine preparation and 37 men among 335 randomized to the control 293 
group. The difference was statistically significant (RR 0.38, 95% CI: 0.21 to 0.69; 294 
participants=620; studies=4; I²=0%; low certainty; figure 8). 295 
 296 
Different unique interventions 297 
 298 
Seven RCTs with unique technical interventions (e.g. needle disinfection, needle size, perineal 299 
cleansing) were identified. Of those, only one study investigating the timepoint of rectal 300 
preparation with povidone-iodine showed significantly reduced infectious complications when 301 






To our knowledge this meta-analysis is the first to assess all the different technical aspects of 306 
prostate biopsy that can possibly reduce the risk of infectious complications. Therefore, it 307 
complements our comprehensive previous meta-analysis on antibiotic prophylaxis of prostate 308 
biopsy.10  In the current analysis we have reported a total of 90 RCTs exploring non-antibiotic 309 
prophylactic strategies including the risk of peri-prostatic nerve block, prostate biopsy route, 310 
number of cores, rectal preparation, and type of needle used. Among the different strategies 311 
assessed in our analysis, transperineal prostate biopsy route and rectal preparation with 312 
povidone-iodine were found as the best interventions (low certainty of evidence) to reduce both 313 
post-biopsy infections and hospitalization. 314 
This meta-analysis is the most comprehensive and recent one evaluating specifically infectious 315 
complications in the head-to-head comparison between transperineal and transrectal route. The 316 
two approaches have been highly debated in recent years with the introduction of MRI targeted 317 
biopsy and diagnostic accuracy.16-20 In addition, there is increasing evidence that MRI 318 
diagnostics can be used to avoid unnecessary prostate biopsies - and thus the corresponding 319 
complications.21,22 Until now, the different MRI targeted biopsy methods have not proved a real 320 
significant difference in terms of PCa detection.23,24 The most recent studies were designed to 321 
assess the PCa detection rates between the two techniques and the potential risk for adverse 322 
events was only a secondary criterion.25,26 Hence, study size of the aforementioned studies was 323 
not calculated to reveal differences in post-biopsy infection, but to investigate diagnostic 324 
accuracy. Thus, two older meta-analyses evaluating also infections complications in 325 
dependence of the biopsy route did not report a significant difference.12,27 On the other hand, a 326 
recent meta-analysis suggested a benefit of transperineal biopsy, which significantly protected 327 
patients from postoperative fever (RR 0.26, 95% CI: 0.14 to 0.28).28 However, all three of these 328 
meta-analyses are limited because they combined estimates from RCTs with those from case-329 
control studies and double counted one study published in duplicate which has a very low 330 
number of post-biopsy infections in both groups.29,30  331 
In the largest systematic review on infectious complications following prostate biopsy (165 332 
studies including 162,577 patients) the standardized prevalence of sepsis was 0.8% in 333 
transrectal and 0.1% in transperineal biopsy and the standardized prevalence of hospitalization 334 
was 1.1% vs. 0.9%, respectively.31 These data are not surprising, as they reinforce the classical 335 
principle for a surgical procedure to choose the lowest possible contamination category in order 336 
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to reduce the rate of infectious complications.32 Our meta-analysis based on 7 RCTs confirmed 337 
this important aspect and showed a significantly lower infection rate using the transperineal 338 
route (RR 0.55, 95% CI: 0.33 to 0.92). Despite the potential logistic challenges attached to the 339 
widespread introduction of the local anesthetic transperineal technique, our findings support 340 
the “TREXIT 2020” approach to abandon transrectal prostate biopsy.17   341 
Another important aspect is the number of biopsy cores taken. Over the years, the number has 342 
increased with the aim of improving diagnostic accuracy. Since one passes repeatedly through 343 
the rectal mucosa by an increased number of biopsy cylinders, one would expect a higher 344 
infection rate. Various cohort studies addressed this important point and were mainly able to 345 
show that the number of biopsy cylinders obtained is independent of postoperative infections.33-346 
35 Our meta-analysis including 11 RCTs shows that the number of cores is not associated with 347 
the risk of infection. This confirms the current guidelines which recommend standard biopsies 348 
in addition to targeted biopsies.2,3  349 
In this context, the question of local anesthesia in the sense of a periprostatic nerve block arises. 350 
Various meta-analyses could impressively show that the periprostatic nerve block significantly 351 
contributes to perioperative pain control compared to an anesthetic gel applied 352 
intrarectally/control.36-39 However, this requires further passages of a needle through the rectum 353 
and the injection of an anesthetic might be associated with the risk of distribution of possible 354 
pathogens. Previous meta-analyses on this topic reported sporadically on post-biopsy 355 
infections, but never primarily investigated the impact of periprostatic nerve block on 356 
infection.38,39 Our analysis including 41 RCTs could show, that there is no increased risk of 357 
infection using periprostatic nerve block. In addition, the number of injections used for the 358 
periprostatic nerve block has no impact on the rate of post-biopsy infections. This is absolutely 359 
consistent with the number of biopsy cores taken as discussed above, which had no influence 360 
on the infection rate. 361 
Since the passage of the needle leads through the contaminated rectal mucosa, there are several 362 
studies that have investigated different parameters of the needle. The diameter, shape, 363 
disinfection and the nature of the needle guide were each investigated in one or two studies, but 364 
no significant advantage in preventing post-biopsy infection was ever detected.40-45   365 
Rectal preparation is a heterogenous practice when transrectal biopsies are planned with some 366 
urologists using enema, chlorhexidine, povidone-iodine applications, full bowel preparation, or 367 
no preparation at all. Here, we found that enema had no impact on postoperative infectious 368 
complications. However, rectal preparation with povidone-iodine prior to prostate biopsy 369 
significantly reduced the risk of infection (RR 0.50, 95% CI: 0.38-0.65), and hospitalization 370 
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(RR 0.38, 95% CI: 0.21-0.69). This is fully in line with a previous meta-analysis.11 The 371 
advantages of rectal povidone-iodine preparation are its simple implementation to daily practice 372 
without largely increasing the cost of the procedure.46 Despite the clear recommendation in 373 
guidelines,2 the value still needs to be spread among urologists.47 374 
 375 
The major strengths of this SR are that, i) it is the most comprehensive analysis on non-376 
antibiotic prophylaxis strategies to prevent infectious complications after prostate biopsy, ii) 377 
we included only RCTs without any language and publication date restriction, iii) it includes 378 
studies also with patients being at higher risk for post-biopsy infection, and iv) it reports with 379 
post-biopsy infections and hospitalization due to infection the two most important adverse 380 
events after prostate biopsy. 381 
 382 
Our study has some limitations which should be acknowledged: i) all infections were summed, 383 
since in many included studies a distinction between severe infections (e.g. sepsis) and mild 384 
infections (urinary tract infection) is not reported in detail, ii) many RCTs were not designed 385 
for the evaluation of postoperative complications particularly regarding peri-prostatic nerve 386 
block, which might underestimate infections and leads to a possible bias, iii) our analysis has 387 
been done without taking the individual antibiotic prophylaxis regimes used in each study into 388 
account, since I² was low or very low in all interventions, and iv) since it was the evaluation of 389 
non-antibiotic measures, the geographical origin of the included RCTs was not considered.    390 
 391 
Conclusions 392 
In this systematic review and meta-analysis we evaluated all published non-antibiotic 393 
prophylaxis regimens to reduce infectious complications following prostate biopsy. We show 394 
with low certainty of evidence, that both transperineal biopsy and rectal preparation with 395 
povidone iodine in transrectal biopsy significantly reduce the risk of infection. Whereas many 396 
concerns are rising to reduce antibiotic resistance and side effects, these non-antibiotic 397 
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Table 1 - Showing unique RCTs 530 
 531 
Legends 532 
Figure 1 – Preferred Reporting Items for Systematic Reviews and Meta-analyses flow chart. 533 
 534 
Figure 2 – Risk of bias assessment. (A) Risk of bias summary according to the judgment of the 535 
review authors on each risk of bias item for each study included. (B) Risk of bias graph 536 
according to the judgment of the review authors for each risk of bias item presented as a 537 
percentage across all the studies included. 538 
 539 
Figure 3 – Comparison of transperineal to transrectal biopsy on infections complications 540 
following prostate biopsy. CI = confidence interval; df = degrees of freedom. 541 
 542 
Figure 4 – Comparison of standard to extended biopsy cores on infections complications 543 
following prostate biopsy. CI = confidence interval; df = degrees of freedom. Note: Emilozzi 544 
2004 reports transperineal biopsy, while all other studies performed transrectal biopsy.  545 
 546 
Figure 5 - Effect of periprostatic nerve block on infections complications following prostate 547 
biopsy. CI = confidence interval; df = degrees of freedom. 548 
 549 
Figure 6 – Effect of rectal preparation with enema on infections complications following 550 
prostate biopsy. CI = confidence interval; df = degrees of freedom. 551 
 552 
Figure 7 – Effect of rectal preparation with povidone-iodine on infections complications 553 
following prostate biopsy. CI = confidence interval; df = degrees of freedom. 554 
 555 
Figure 8 – Effect of rectal preparation with povidone-iodine on hospitalization following 556 
prostate biopsy. CI = confidence interval; df = degrees of freedom. 557 
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To identify which non-antibiotic strategies could reduce the risk of infectious complications 47 
following prostate biopsy. 48 
 49 
Materials and Methods 50 
We performed a literature search on MEDLINE, Embase, and Cochrane Database for 51 
randomized controlled trials (RCTs) (Inception to May 2020) assessing non-antibiotic 52 
interventions in prostate biopsy. Primary outcome was pooled infectious complications (fever, 53 
sepsis and symptomatic UTI) and secondary outcome was hospitalization. Cochrane risk of bias 54 
tool and GRADE approach were used to assess the bias and the certainty of evidence. Protocol 55 
was registered with PROSPERO (CRD42015026354).  56 
 57 
Results 58 
90 RCTs (16,941 participants) were included in the analysis with 83 RCTs being categorized 59 
into one of ten different interventions. Transperineal biopsy was associated with significantly 60 
reduced infectious complications as compared to transrectal biopsy (RR 0·55, 95% CI 0·33-61 
0·92, p=0·02, I²=0%, participants=1330, studies=7). Rectal preparation with povidone-iodine 62 
was also shown to reduce infectious complications (RR 0·50, 95% CI 0·38-0·65, p<0·000001, 63 
I²=27%, participants=1686, studies=8) as well as hospitalization (RR 0·38, 95% CI 0·21-0·69, 64 
p=0·002, I²=0%, participants=620; studies=4). We found no difference in infectious 65 
complications/hospitalization for six other interventions: number of biopsy cores, periprostatic 66 
nerve block (PPNB), number of injections for PPNB, needle guide type, needle type, and rectal 67 
preparation with enema. In two interventions (needle diameter, rectal preparation with 68 
chlorhexidine) meta-analysis was not possible. Finally, seven studies had unique interventions. 69 
The certainty of evidence was rated as low/very low for all interventions. 70 
 71 
Conclusions 72 
Transperineal biopsy significantly reduces infectious complications compared to transrectal 73 
biopsy and should therefore be preferred. If transrectal biopsy is performed, rectal preparation 74 
with povidone-iodine is highly recommended. The other investigated non-antibiotic strategies 75 





In 2019 more than 190,000 new cases of prostate cancer (PCa) are diagnosed in the USA 79 
causing more than 33,000 deaths1. Worldwide prostate cancer accounts for a significant 80 
proportion of male cancer and mortality. PCa diagnosis is based on biopsies following patient 81 
evaluation for an elevated PSA or abnormal digital rectal examination and there is an increasing 82 
role for pre-biopsy MRI.2,3 Prostatic biopsy remains the keystone for diagnosis and 83 
management of PCa and the most commonly performed diagnostic procedure in urology with 84 
more than 2 million per year.4 Therefore, many efforts have been made to prevent infectious 85 
complications which account for the major adverse events with up to 7% of infections and 3.1% 86 
of sepsis depending of antibiotic prophylaxis regimens.3 Even if an antibiotic prophylaxis is 87 
recommended by every guideline, the incidence of infectious complications is not negligible 88 
and its prevention of utmost importance.2,3 In addition, both the induction of resistance through 89 
the use of antibiotics and side effects must be considered.5 Post-biopsy infections have been 90 
increasing over the last few years.6,7 Thus, antibiotic interventions such as targeted antibiotic 91 
prophylaxis based on rectal swab culture as well as augmented antibiotic prophylaxis applying 92 
more than one antibiotic were introduced to reduce infectious complications.8,9 In a 93 
comprehensive meta-analysis we have recently compiled the evidence of various interventions 94 
for antibiotic prophylaxis.10 In addition to antibiotics different aspects and modalities of biopsy 95 
techniques have been investigated with a view to minimizing adverse events. Among them, 96 
biopsy route, enema, and number of cores have been already suggested as potential factors to 97 
reduce the infectious risk.11,12 Nevertheless, no systematic analysis is available evaluating 98 
various technical aspects of prostate biopsy for reducing post-biopsy infections. 99 
The aim of our comprehensive systematic review and meta-analysis was to investigate whether 100 
and to what extent any non-antibiotic interventions reduce the risk of infectious complications 101 
following prostate biopsy.  102 
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Materials and Methods 103 
 104 
Evidence acquisition 105 
We followed the PRISMA guidance and the Cochrane Handbook for systematic reviews of 106 
interventions.13,14 The protocol was registered at PROSPERO (CRD42015026354). The 107 
detailed PICO (Population, Intervention, Comparison and Outcomes) is provided in 108 
supplementary appendix 1.  109 
 110 
Literature search 111 
The Medline, Embase, LILACS, CENTRAL, Cochrane Database of Systematic reviews 112 
databases and clinicaltrial.gov were searched for randomized controlled trials (RCTs) (last 113 
search 27th May 2020). The grey literature was searched through opengrey.eu and oclc.org. 114 
Potentially-eligible trials were also identified by searching the reference lists of trials, reviews, 115 
and health technology assessment reports (Y.Y). There were no date or language restrictions. 116 
In order to avoid publication bias, abstracts characterized as RCTs, but for which published 117 
manuscripts were not yet available, were included in this systematic review with meta-analysis, 118 
as were funnel plots for interventions involving more than 10 studies. The search strategy is 119 
included in supplementary appendix 2. 120 
 121 
Types of outcome measures 122 
Primary outcome: 123 
x Pooled infectious complications (calculated by summing all types of infectious 124 
complications reported i.e. fever, sepsis, symptomatic UTI). This approach was chosen 125 
since in many studies investigating post-biopsy complications, a distinction between 126 
severe infections (e.g. sepsis) and mild infections (e.g. cystitis) is not reported in detail 127 
(supplementary table 1). 128 
Secondary outcome: 129 
x Hospitalization due to infectious complications.  130 
 131 
Data collection and analysis 132 
Abstract screening, full-text screening, and data extraction was independently performed by 133 
two reviewers (A.P., B.P., or R.V.). For each disagreement, another reviewer (M.I.O., S.M.) 134 
was consulted. All the study authors were contacted to provide missing information if 135 
5 
 
necessary. Eight non-English articles were evaluated in the corresponding languages by 136 
members of the author team with appropriate language skills (4×Chinese: Y.Y., 1×French: B.P., 137 
F.B., 1×Spanish: A.P., B.P., 2×Turkish: Mete Cek, former EAU Guideline panel member). One 138 
Japanese article and two Korean articles were translated into English by professional 139 
translators. Among the 90 RCTs there are also eight studies that have so far only been published 140 
as abstracts. The risk of bias (RoB) was independently assessed by two reviewers (R.V., K.D.), 141 
by using the Cochrane RoB assessment tool.14,15 Any disagreements were resolved via 142 
discussion or consultation with another reviewer (M.I.O., S.M.). The GRADE approach was 143 
used to assess the certainty of evidence for each comparison (M.I.O., S.M.).14 144 
 145 
Statistical analysis 146 
The meta-analysis was performed using Review Manager (RevMan) version 5.3. A fixed-147 
effects model was used to calculate pooled estimates of treatment effects across similar studies 148 
and their 95% confidence intervals (CIs). We used risk ratio (RR) for dichotomous outcomes. 149 
We identified heterogeneity by visually inspecting forest plots and using a standard x2 test with 150 
a significance level of α=0.1. We also considered the I2 statistic, which quantifies inconsistency 151 
across trials to assess the impact of heterogeneity on the meta-analysis. Where there was 152 
evidence of heterogeneity, we attempted to determine possible reasons by examining individual 153 




Literature search and characteristics of the included studies 158 
We identified 3111 citations, of those 284 were selected for full-text screening. Reasons for 159 
exclusion are provided in supplementary table 2. A total of 90 RCTs were included in the SR 160 
(supplementary appendix 3). The inclusion process is graphically illustrated in a PRISMA 161 
diagram (figure 1). For all included studies we provide detailed study characteristics in 162 
supplementary table 3. Of the 90 RCTs 83 studies could be categorized into one of ten different 163 
interventions, while 7 studies had unique interventions. Sensitivity analyses for the individual 164 
interventions showed that no changes occurred with or without the data of the eight included 165 
abstracts, which have not yet been published as full-text. 166 
 167 
Risk of Bias (RoB) assessment 168 
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The RoB assessment is graphically illustrated in figure 2.  It is noticeable that the majority of 169 
studies have an unclear RoB regarding random sequence generation, allocation concealment 170 
and blinding of outcome assessment. Furthermore, most studies have been conducted without 171 
blinding patients or personnel, which is certainly also due to the type of technical intervention. 172 
A funnel plot from the interventions with more than 10 studies (PPNB) showed no asymmetry 173 
(details in supplementary appendix 4). 174 
 175 
Study heterogeneity 176 
The I² statistic was 0% in all cases except Intervention 8 (povidone-iodine) where it was 27%. 177 
Since the p-values changed only marginally when using random-effect models for all 178 
interventions and endpoints, we used fixed-effect models throughout. 179 
 180 
GRADE 181 
The certainty of evidence was mainly downgraded due to study design, imprecision and risk of 182 
bias (details in supplementary appendix 5). 183 
 184 
Intervention 1: Impact of biopsy route  185 
 186 
A total of seven RCTs including 1330 patients compared the impact of biopsy route on 187 
infectious complications (supplementary appendix 3). There were significantly lower infectious 188 
complications when the transperineal route was performed (22 events among 673 men) 189 
compared to the transrectal route (37 events among 657 men) (RR 0.55, 95 CI: 0.33 to 0.92; 190 
participants=1330; studies=7; I²=0%; low certainty; figure 3).  191 
Data on hospitalization were reported in three studies with a total of 685 patients. While two 192 
hospitalizations were necessary in 346 patients in the transperineal group, hospitalization was 193 
reported in six cases out of 339 patients undergoing transrectal biopsy without any statistical 194 
difference (RR 0.38, 95 CI: 0.09 to 1.61; participants=685; studies=3; I²=0%; very low 195 
certainty; supplementary figure 1). 196 
 197 
Intervention 2: Impact of number of biopsy cores 198 
 199 
The impact of the number of cores was evaluated in 11 studies including 2626 men undergoing 200 
prostate biopsy (supplementary appendix 3). While ten studies performed transrectal biopsy 201 
one study used the transperineal approach. MA showed 38 infectious complications in 1320 202 
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men randomized to standard and 47 in those 1306 randomized to extended number of cores. 203 
The comparison was not significant (RR 0.80, 95% CI: 0.53 to 1.22; participants=2230; 204 
studies=9; I²=0%; low certainty; figure 4).  205 
Of those studies, only five studies presented data on hospitalization following prostate biopsy. 206 
There was one case of hospitalization among 415 men in the standard group, while four cases 207 
occurred among 411 men in the extended biopsy scheme group. The comparison was not 208 
significant (RR 0.34, 95% CI: 0.05 to 2.13; participants=306; studies=2; I²=0%; very low 209 
certainty; supplementary figure 2). 210 
 211 
Intervention 3: Impact of periprostatic nerve block 212 
 213 
Pain after periprostatic nerve block (PPNB) during biopsy was evaluated in 41 RCTs and 214 
infectious outcomes were reported in a total of 5540 men (supplementary appendix 3). There 215 
were 61 infectious complications among 2633 patients randomized to periprostatic nerve block 216 
and 73 among 2907 patients randomized to no nerve block/control. The comparison was not 217 
significant (RR 1.07, 95% CI: 0.77 to 1.48; participants=3857; studies=26; I²=0%; very low 218 
certainty; figure 5). 219 
Among these studies, only 14 reported hospitalization with 13 cases of hospitalization among 220 
971 men in the PPNB group, while 15 cases occurred among 1128 men in the group without 221 
PPNB. The comparison was not significant (RR 1.13, 95% CI: 0.59 to 2.16; participants=1469; 222 
studies=9; I²=0%; very low certainty; supplementary figure 3). 223 
 224 
Intervention 4: Impact of number of injections for periprostatic nerve block 225 
 226 
Six studies compared the number of injections applied for PPNB and assessed post-biopsy 227 
infections (supplementary appendix 3). MA showed five infections among 459 men 228 
randomized to standard number of injections and four among 468 men randomized to extended 229 
PPNB. The difference was not statistically significant (RR 1.30, 95 CI: 0.35 to 4.76; 230 
participants=478; studies=3; I²=0%; low certainty; supplementary figure 4). 231 
Two studies reported hospitalization with two patients being hospitalized among 147 men 232 
randomized to standard PPNB and two men among 153 randomized to extended PPNB. The 233 
difference was not statistically significant (RR 1.05, 95 CI: 0.15 to 7.32; participants=300; 234 




Intervention 5: Impact of disposable needle guides 237 
 238 
Two RCTs evaluated the use of disposable needle guides compared to reusable guides in a total 239 
of 253 patients (supplementary appendix 3).  240 
There were nine events among 113 men randomized to disposable needle guides and 22 events 241 
among 140 men randomized to reusable needle guides. The difference was not statistically 242 
significant (RR 0.51, 95% CI: 0.24 to 1.06; participants=253; studies=2; I²=0%; very low 243 
certainty; supplementary figure 6). 244 
Both studies evaluated the impact on hospitalization. While four events occurred in 113 men 245 
randomized to the disposable needle guide group, nine events were recorded in 140 men of the 246 
reusable needle guide group. The difference was not statistically significant (RR 0.55, 95% CI: 247 
0.17 to 1.74; participants=253; studies=2; I²=0%; very low certainty; supplementary figure 7). 248 
 249 
Intervention 6: Impact of needle type 250 
 251 
Only two studies investigated the impact of a coaxial needle versus a non-coaxial needle and 252 
reported on infectious complications (supplementary appendix 3). Data analysis revealed no 253 
infections in 171 men in the coaxial needle arm, while one case occurred among 171 men in 254 
the group randomized to the non-coaxial biopsy needles. MA was not possible, because of zero 255 
events in one study. Hospitalization was reported in only one of the two studies and did not 256 
occur in any among the 240 patients.  257 
 258 
Intervention 7: Impact of needle diameter 259 
 260 
The impact of needle diameter was investigated in two studies (supplementary appendix 3). 261 
Data analysis revealed no infections in 133 men randomized to the smaller needle diameter, 262 
while one case occurred among 163 men in the group randomized to the larger needle diameter. 263 
MA was not possible, because of zero events in one study. Hospitalization was not reported as 264 
an endpoint in any study. 265 
 266 
Intervention 8: Impact of rectal preparation with enema 267 
Four RCTs evaluated rectal preparation with enema (supplementary appendix 3). Among 336 268 
men randomized to enema 30 events were recorded, while among 335 men in control group 31 269 
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events were reported. The difference was not statistically significant (RR 0.96, 95% CI: 0.60 to 270 
1.53; participants=671; studies=4; I²=0%; low certainty; figure 6). 271 
Only two studies with each 231 patients per group reported on hospitalization with nine events 272 
in the enema and eight events in the control group. This comparison was not statistically 273 
significant (RR 1.13, 95% CI: 0.44 to 2.86; participants=462; studies=2; I²=0%; low certainty; 274 
supplementary figure 8). 275 
 276 
Intervention 9: Impact of rectal preparation with chlorhexidine 277 
 278 
Two studies investigated the influence of rectal preparation with chlorhexidine (supplementary 279 
appendix 3). Although both studies report infectious complications separately for the 280 
intervention and control groups, the primary outcome cannot be meta-analyzed due to a possible 281 
double case count in one of the studies. 282 
 283 
Intervention 10: Impact of rectal preparation with povidone-iodine 284 
 285 
Nine studies evaluated the use of rectal preparation with povidone-iodine (supplementary 286 
appendix 3) in a total of 1936 patients. MA showed 61 infections among 930 men in the 287 
povidone-iodine group and 131 among 1006 in the control group. The difference was 288 
statistically significant (RR 0.50, 95% CI: 0.38 to 0.65; participants=1686; studies=8; I²=27%; 289 
low certainty; figure 7).  290 
 291 
Four studies reported on hospitalization with a total of 12 men hospitalized among 285 men 292 
randomized to povidone iodine preparation and 37 men among 335 randomized to the control 293 
group. The difference was statistically significant (RR 0.38, 95% CI: 0.21 to 0.69; 294 
participants=620; studies=4; I²=0%; low certainty; figure 8). 295 
 296 
Different unique interventions 297 
 298 
Seven RCTs with unique technical interventions (e.g. needle disinfection, needle size, perineal 299 
cleansing) were identified. Of those, only one study investigating the timepoint of rectal 300 
preparation with povidone-iodine showed significantly reduced infectious complications when 301 






To our knowledge this meta-analysis is the first to assess all the different technical aspects of 306 
prostate biopsy that can possibly reduce the risk of infectious complications. Therefore, it 307 
complements our comprehensive previous meta-analysis on antibiotic prophylaxis of prostate 308 
biopsy.10  In the current analysis we have reported a total of 90 RCTs exploring non-antibiotic 309 
prophylactic strategies including the risk of peri-prostatic nerve block, prostate biopsy route, 310 
number of cores, rectal preparation, and type of needle used. Among the different strategies 311 
assessed in our analysis, transperineal prostate biopsy route and rectal preparation with 312 
povidone-iodine were found as the best interventions (low certainty of evidence) to reduce both 313 
post-biopsy infections and hospitalization. 314 
This meta-analysis is the most comprehensive and recent one evaluating specifically infectious 315 
complications in the head-to-head comparison between transperineal and transrectal route. The 316 
two approaches have been highly debated in recent years with the introduction of MRI targeted 317 
biopsy and diagnostic accuracy.16-20 In addition, there is increasing evidence that MRI 318 
diagnostics can be used to avoid unnecessary prostate biopsies - and thus the corresponding 319 
complications.21,22 Until now, the different MRI targeted biopsy methods have not proved a real 320 
significant difference in terms of PCa detection.23,24 The most recent studies were designed to 321 
assess the PCa detection rates between the two techniques and the potential risk for adverse 322 
events was only a secondary criterion.25,26 Hence, study size of the aforementioned studies was 323 
not calculated to reveal differences in post-biopsy infection, but to investigate diagnostic 324 
accuracy. Thus, two older meta-analyses evaluating also infections complications in 325 
dependence of the biopsy route did not report a significant difference.12,27 On the other hand, a 326 
recent meta-analysis suggested a benefit of transperineal biopsy, which significantly protected 327 
patients from postoperative fever (RR 0.26, 95% CI: 0.14 to 0.28).28 However, all three of these 328 
meta-analyses are limited because they combined estimates from RCTs with those from case-329 
control studies and double counted one study published in duplicate which has a very low 330 
number of post-biopsy infections in both groups.29,30  331 
In the largest systematic review on infectious complications following prostate biopsy (165 332 
studies including 162,577 patients) the standardized prevalence of sepsis was 0.8% in 333 
transrectal and 0.1% in transperineal biopsy and the standardized prevalence of hospitalization 334 
was 1.1% vs. 0.9%, respectively.31 These data are not surprising, as they reinforce the classical 335 
principle for a surgical procedure to choose the lowest possible contamination category in order 336 
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to reduce the rate of infectious complications.32 Our meta-analysis based on 7 RCTs confirmed 337 
this important aspect and showed a significantly lower infection rate using the transperineal 338 
route (RR 0.55, 95% CI: 0.33 to 0.92). Despite the potential logistic challenges attached to the 339 
widespread introduction of the local anesthetic transperineal technique, our findings support 340 
the “TREXIT 2020” approach to abandon transrectal prostate biopsy.17   341 
Another important aspect is the number of biopsy cores taken. Over the years, the number has 342 
increased with the aim of improving diagnostic accuracy. Since one passes repeatedly through 343 
the rectal mucosa by an increased number of biopsy cylinders, one would expect a higher 344 
infection rate. Various cohort studies addressed this important point and were mainly able to 345 
show that the number of biopsy cylinders obtained is independent of postoperative infections.33-346 
35 Our meta-analysis including 11 RCTs shows that the number of cores is not associated with 347 
the risk of infection. This confirms the current guidelines which recommend standard biopsies 348 
in addition to targeted biopsies.2,3  349 
In this context, the question of local anesthesia in the sense of a periprostatic nerve block arises. 350 
Various meta-analyses could impressively show that the periprostatic nerve block significantly 351 
contributes to perioperative pain control compared to an anesthetic gel applied 352 
intrarectally/control.36-39 However, this requires further passages of a needle through the rectum 353 
and the injection of an anesthetic might be associated with the risk of distribution of possible 354 
pathogens. Previous meta-analyses on this topic reported sporadically on post-biopsy 355 
infections, but never primarily investigated the impact of periprostatic nerve block on 356 
infection.38,39 Our analysis including 41 RCTs could show, that there is no increased risk of 357 
infection using periprostatic nerve block. In addition, the number of injections used for the 358 
periprostatic nerve block has no impact on the rate of post-biopsy infections. This is absolutely 359 
consistent with the number of biopsy cores taken as discussed above, which had no influence 360 
on the infection rate. 361 
Since the passage of the needle leads through the contaminated rectal mucosa, there are several 362 
studies that have investigated different parameters of the needle. The diameter, shape, 363 
disinfection and the nature of the needle guide were each investigated in one or two studies, but 364 
no significant advantage in preventing post-biopsy infection was ever detected.40-45   365 
Rectal preparation is a heterogenous practice when transrectal biopsies are planned with some 366 
urologists using enema, chlorhexidine, povidone-iodine applications, full bowel preparation, or 367 
no preparation at all. Here, we found that enema had no impact on postoperative infectious 368 
complications. However, rectal preparation with povidone-iodine prior to prostate biopsy 369 
significantly reduced the risk of infection (RR 0.50, 95% CI: 0.38-0.65), and hospitalization 370 
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(RR 0.38, 95% CI: 0.21-0.69). This is fully in line with a previous meta-analysis.11 The 371 
advantages of rectal povidone-iodine preparation are its simple implementation to daily practice 372 
without largely increasing the cost of the procedure.46 Despite the clear recommendation in 373 
guidelines,2 the value still needs to be spread among urologists.47 374 
 375 
The major strengths of this SR are that, i) it is the most comprehensive analysis on non-376 
antibiotic prophylaxis strategies to prevent infectious complications after prostate biopsy, ii) 377 
we included only RCTs without any language and publication date restriction, iii) it includes 378 
studies also with patients being at higher risk for post-biopsy infection, and iv) it reports with 379 
post-biopsy infections and hospitalization due to infection the two most important adverse 380 
events after prostate biopsy. 381 
 382 
Our study has some limitations which should be acknowledged: i) all infections were summed, 383 
since in many included studies a distinction between severe infections (e.g. sepsis) and mild 384 
infections (urinary tract infection) is not reported in detail, ii) many RCTs were not designed 385 
for the evaluation of postoperative complications particularly regarding peri-prostatic nerve 386 
block, which might underestimate infections and leads to a possible bias, iii) our analysis has 387 
been done without taking the individual antibiotic prophylaxis regimes used in each study into 388 
account, since I² was low or very low in all interventions, and iv) since it was the evaluation of 389 
non-antibiotic measures, the geographical origin of the included RCTs was not considered.    390 
 391 
Conclusions 392 
In this systematic review and meta-analysis we evaluated all published non-antibiotic 393 
prophylaxis regimens to reduce infectious complications following prostate biopsy. We show 394 
with low certainty of evidence, that both transperineal biopsy and rectal preparation with 395 
povidone iodine in transrectal biopsy significantly reduce the risk of infection. Whereas many 396 
concerns are rising to reduce antibiotic resistance and side effects, these non-antibiotic 397 
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Table 1 - Showing unique RCTs 530 
 531 
Legends 532 
Figure 1 – Preferred Reporting Items for Systematic Reviews and Meta-analyses flow chart. 533 
 534 
Figure 2 – Risk of bias assessment. (A) Risk of bias summary according to the judgment of the 535 
review authors on each risk of bias item for each study included. (B) Risk of bias graph 536 
according to the judgment of the review authors for each risk of bias item presented as a 537 
percentage across all the studies included. 538 
 539 
Figure 3 – Comparison of transperineal to transrectal biopsy on infections complications 540 
following prostate biopsy. CI = confidence interval; df = degrees of freedom. 541 
 542 
Figure 4 – Comparison of standard to extended biopsy cores on infections complications 543 
following prostate biopsy. CI = confidence interval; df = degrees of freedom. Note: Emilozzi 544 
2004 reports transperineal biopsy, while all other studies performed transrectal biopsy.  545 
 546 
Figure 5 - Effect of periprostatic nerve block on infections complications following prostate 547 
biopsy. CI = confidence interval; df = degrees of freedom. 548 
 549 
Figure 6 – Effect of rectal preparation with enema on infections complications following 550 
prostate biopsy. CI = confidence interval; df = degrees of freedom. 551 
 552 
Figure 7 – Effect of rectal preparation with povidone-iodine on infections complications 553 
following prostate biopsy. CI = confidence interval; df = degrees of freedom. 554 
 555 
Figure 8 – Effect of rectal preparation with povidone-iodine on hospitalization following 556 
prostate biopsy. CI = confidence interval; df = degrees of freedom. 557 
Abbreviations and Acronyms 
 
CI = confidence interval 
GRADE = Grading of Recommendations, Assessment, Development and Evaluations 
MA = meta-analysis 
MRI = Magnetic resonance imaging 
PB = prostate biopsy 
PCa = prostate cancer 
PPNB = periprostatic nerve block 
RCT = randomized controlled trials 
RoB = risk of bias 
RR = risk ratio 
SR = systematic review 
UTI = urinary tract infection 
Key of Definitions for Abbreviations (only include abbreviations
used 3 times or more in manuscript)
 
Table 1: Unique RCTs 
 
Study and Year Intervention Outcome 
Bingqian 2009 PPNB plus intraprostatic injection vs. control 
Infectious complications not 
significantly different 
Bolat 2016 
Transperineal prostatic nerve block 
vs. transrectal periprostatic nerve 
block 
Infectious complications not 
significantly different# 
Costa 2019 
Rectal preparation with povidone-
iodine plus formalin needle 
disinfection vs. control 
Lower complications in intervention 
group, but not statistically significant 
De Nunzio 2015 Enema vs. full bowel preparation Infectious complications not significantly different* 
Koc 2010 Needle washing with povidone-iodine vs. control 
Lower complications in intervention 
group, but not statistically significant 
Taher 2014 
Perineal cleansing vs. no perineal 
cleansing in transrectal prostate 
biopsy 
Lower complications in intervention 
group, but not statistically significant 
Yu 2015 
Timepoint of rectal preparation with 
povidone-iodine (before vs. after vs. 
before plus after) 
Significantly reduced infectious 
complications in groups with rectal 
preparation before biopsy 
# raw data provided from authors; febrile UTI: 3 vs. 2 
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Supplementary appendix 1:  PICO elements - Post prostate biopsy infection 
 
PICO elements Characteristics 
Question Which strategies are effective for reducing the risk of infectious 
complications for men undergoing prostate biopsy? 
Objectives • To determine the effective strategies for reducing  infectious 
complications of prostate biopsy 
• To determine whether specific strategies give most benefit for 
patient sub-groups identified as being at greater risk for infective 
complications by using sensitivity analysis on relevant subgroups   
Population • Men who undergo prostate biopsies using any strategy or approach; 
includes men with suspicion of prostate cancer, or those already 
diagnosed with prostate cancer (e.g. active surveillance) or those 
who undergo biopsy to confirm local recurrence to consider salvage 
treatment. 
• Exclusion criteria: Men who do not have prostate biopsies (i.e. for 
inclusion, all studies must include only men who have had biopsies, 
and mixed populations are excluded). 
• Subgroups of interest:  
(1) Proportion of men with factors conferring higher risk of infective 
complications: 
• Patient age (< 75 years vs ≥75 years) 
• Immunosuppressive drugs or co-morbidity (yes/no) 
• Valvular heart disease (y/n) 
• CNS disorder (y/n) 
• Previous biopsy (y/n) 
• Antibiotics in previous 6 months (y/n) 
• Hospitalization in previous 6 months (y/n) 
• Urethral instrumentation in previous 6 months (y/n) 
• Asymptomatic bacteriuria (y/n) 
• History of prostatitis (y/n) 
• Indwelling or intermittent urinary catheter (y/n) 
• Recent travel areas with high prevalence of  multi-resistant 
E. coli high risk area (y/n) 
• PSA (< 10/≥ 10) 
• Prostate volume (< 40 ml/≥ 40 ml) 
• Prostate cancer in histology (y/n) 
• Others defined by trialists 
Interventions/ 
Exposure 
Experimental interventions (including variations and co-interventions) 
 
(1) Antibiotics: (a) Types: fluoroquinolones vs gentamicin vs metronidazole 
vs carbapenem vs trimethoprim/sulphamethoxazole vs Co-amoxiclav vs 
combinations of any two or more vs any other antibiotic judged relevant by 
Supplementary Appendix 1 PICO
reviewer; (b) Dose of antibiotic (standard vs non-standard, as defined by 
present EAU Guidelines); (c) Timing (for single doses: ≤1 hour vs >1 hour); (d) 
Duration (single vs multiple within 24 hours vs multiple within >24 hours); 
(e) Route of antimicrobial administration (Oral vs Rectal vs 
Intramuscular/Intravenous);  
(2) Co-interventions: (a) Use of rectal swab versus no rectal swab to guide 
prophylaxis; (b) treatment of asymptomatic bacteriuria ( ABU) vs no 
treatment prior to biopsy; (c) Use of rectal cleansing or preparation, 
including enema, disinfectant or antiseptic solution, or washing, prior to 
biopsy vs no use. 
(3) Technical aspects: (a) number of cores, (b) needle size, (c) needle dwell 
time, (d) transrectal vs perineal, (d) fusion vs no fusion, (e) local injected 
anaesthetic vs no local anaesthetic 
(4) Any other intervention judged relevant by reviewer 
*Control interventions: Placebo or no treatment; standard or alternative 
prophylaxis as defined by trialist 
Comparisons • Experimental vs Control 
• Experimental vs Experimental 
• Experimental only not included (but single-arm case series reporting 
on bacterial resistance will be included, and those reporting on other 
outcomes will be retained for discussion if relevant)  
Outcomes Primary outcomes 
x Symptomatic infectious complication  
 
Secondary outcomes  
x Asymptomatic bacteriuria 
x Hospitalization due to infective complications 
x Mortality 
x Adverse effects of antimicrobial strategy 
x Change in bacterial resistance (before, after biopsy 
 Study types main question 
• RCTs 
• Non-randomised comparative studies for those interventions, where 
RCTs are not available 
 
Study types sub-question on patients risk factor analysis  
• RCTs for Cochrane review 
• Non-randomised comparative studies 
• Single-arm studies for anti-microbial resistance 
Restriction of date of publication 
• No restriction  
 
Language restrictions 
• No language restriction 
 
Key words 
Both medical subject heading (MeSH) and free text terms as well as 
variations of root word will be searched. 
 
Key terms related to “prostate” or “prostate neoplasms” will be combined 
using the set operator AND key terms related to “biopsy or biopsies” AND 
key terms related to “anti-infective agents or disinfectants or technical 
modifications” AND key terms related to “prophylaxis or prevention”.  
 
Databases 
Embase (OvidSP)  
Medline (OvidSP) 
Cochrane databases (Cochrane Central Register of Controlled  Trials, 
Cochrane Database of Systematic Reviews and Cochrane  Health Technology 
Assessment)  
clinicaltrials.gov  
WHO international Clinical Trials Registry Platform (ICTRP) 
 
Confounders 
(confounders will be 
used for risk of bias 
assessment only and 
will not affect 
decisions on whether 
to include or exclude 
studies) 
Factors that may directly affect efficacy of interventions and should be 
balanced between groups 
• Patient age (< 75 years vs ≥75 years) 
• Presence of multi-resistant E. coli 
• In urine 
• In faeces 
• Asymptomatic bacteriuria (y/n) 
• Indwelling or intermittent urinary catheter (y/n) 
 
Supplementary appendix 2:   
 
Search Strategy Search Strategy (Medline and Embase via OvidSP, from inception to May 
27, 2020) 
 
1. exp prostate/ 
2. exp Prostatic Neoplasms/ or exp prostate tumor/ 
3. (prostatic or prostate).ti,ab,kw. 
4. or/1-3 
5. exp biopsy/ 
6. (biopsy or biopsies or biopsied).ti,ab,kw. 
7. or/5-6 
8. 4 and 7 
9. exp antiinfective agent/ 
10. exp Anti-Infective Agents/ 
11. exp quinolone derivative/ or exp Quinolones/ 
12. exp metronidazole/ 
13. exp gentamicin/ or exp Gentamicins/ 
14. exp carbapenem/ or exp Carbapenems/ 
15. exp trimethoprim/ 
16. exp sulfamethoxazole/ 
17. exp amoxicillin plus clavulanic acid/ 
18. exp piperacillin/ 
19. exp cotrimoxazole/ 
20. exp netilmicin/ 
21. exp cefuroxime/ 
22. exp norfloxacin/ 
23. exp ciprofloxacin/ 
24. exp ofloxacin/ 
25. exp tinidazole/ 
26. exp ceftriaxone/ 
27. exp Disinfection/ or exp Disinfectants/ or exp disinfectant agent/ 
28. (antibiotic* or antibacterial or anti bacterial or antiseptic* antimicrobial* or anti infect* 
or antiinfect* or disinfectant* or disinfection).tw. 
29. (fluoroquinolone* or quinolone* or gentamicin* or metronidazole or falgyl).tw. 
30. (carbapenem or trimethoprim or sulphamethoxazole or Co-amoxiclav).tw. 
31. (clavulanic acid or sulfonamide* or aminoglycoside* or cephalosporin* or piperacillin or 
cefuroxime or norfloxacin).tw. 
32. (ciprofloxacin or ofloxacin or tinidazole or cephtriaxon or ceftriaxone or netilmicin or 
netromycine).tw. 
33. (cotrimoxazole or co-trimoxazole or sulfamethoxazole or (beta lactamase adj2 
(inhibitors* or antagonist*))).tw. 
34. exp sulfonamide/ or exp Sulfonamides/ 
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35. exp aminoglycoside/ or exp Aminoglycosides/ 
36. exp cephalosporin/ or exp Cephalosporins/ 
37. exp beta lactamase inhibitor/ or exp beta-Lactamase Inhibitors/ 
38. (povidone iodine or betadine or iodophor or povidone).tw. 
39. exp povidone iodine/ or exp povidone/ or exp iodophor/ or exp Iodophors/ 
40. or/9-39 
41. exp prophylaxis/ 
42. exp Antibiotic Prophylaxis/ or exp Pre-Exposure Prophylaxis/ 
43. exp prevention/ 
44. (prophyla* or prevent* or reduced or reduction or reducing).tw. 
45. (pre-biopsy or prebiopsy or pre-biopsies or prebiopsies).ti,ab. 
46. (pre-operativ* or pre-intervention* or pre-procedure* or preoperativ* or preintervention 
or preprocedure*).tw. 
47. (before or prior).tw. 
48. or/41-47 
49. 8 and 40 and 48 
50. ((rectal or rectum) adj3 (swab or cleaning or washing or preparation* or sterilization)).tw. 
51. exp enema/ or enema.tw. 
52. ((transrectal or trans-rectal) and (transperineal or perineal)).tw. 
53. (fusion adj3 (guided or guidance or guide or guiding)).tw. 
54. exp local anesthetic agent/ or exp Anesthetics, Local/ or ((local or topical) adj2 
(anaesthetic* or anesthetic*)).tw. 
55. (needle adj3 (size or dwell time)).tw. 
56. (dipstick urinalysis or midstream specimen).tw. 
57. (technical modification* or technical alternation*).tw. 
58. (number adj2 cores).tw. 
59. or/50-58 
60. 8 and 48 and 59 
61. Biopsy, Needle/mt 
62. ((compared adj5 protocol) or protocols).tw. 
63. or/61-62 
64. 8 and 63 
65. 49 or 60 or 64 






72. double-blind*.mp. or blind*.tw. 
73. clinical trial:.mp. 
74. or/66-73 
75. 65 and 74 
76. note/ or editorial/ or letter/ or Comment/ or news/ 
77. case report/ or case reports/ or case report.ti. 
78. (exp animals/ or exp animal/ or exp nonhuman/ or exp animal experiment/ or animal 
model/ or animal tissue/ or non human/ or (rat or rats or mice or mouse or swine or 
porcine or murine or sheep or lambs or pigs or piglets or rabbit or rabbits or cat or cats or 
dog or dogs or cattle or bovine or monkey or monkeys or trout or marmoset$1).ti.) not 
(humans/ or human/ or human experiment/ or (human* or men or women or patients or 
subjects).tw.) 
79. or/76-78 
80. 75 not 79 
81. remove duplicates from 80 
Note: The search strategy included both antibiotic and non-antibiotic prophylaxis. For the 
present publication only studies with non-antibiotic interventions were used.   
Supplementary appendix 3:  References of included RCTs 
 
All included RCTs 
 
1. Adamakis I, Mitropoulos, D, Haritopoulos, K et al: Pain during transrectal ultrasonography guided prostate 
biopsy: a randomized prospective trial comparing periprostatic infiltration with lidocaine with the intrarectal 
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Supplementary appendix 2:   
 
 
Funnel plot of comparison: Intervention 3 - periprostatic nerve block vs. no periprostatic nerve 
block, outcome: Pooled infectious complications. Publication bias was not suspected as there is 
symmetrical scatter of the studies in the funnel plot. 
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Supplementary appendix 5: GRADE for the ten different interventions 
 
Intervention 1  
 
Summary of findings:  
Transperineal compared to transrectal prostate biopsy for prevention of infectious complications 
following prostate biopsy 
Patient or population: Prevention of infectious complications following prostate biopsy  
Setting: Patients undergoing prostate biopsy 
Intervention: Transperineal prostate biopsy 
Comparison: Transrectal prostate biopsy 
Outcomes 
Anticipated absolute effects* 
(95% CI)  
Relative effect 




Certainty of the 
evidence 
(GRADE)  









56 per 1,000  
31 per 1,000 
(19 to 52)  RR 0.55 (0.33 to 0.92)  
1330 
(7 RCTs)  
⨁⨁◯◯ 
LOW a 
Transperineal biopsy likely results in 
a reduction in pooled infectious 
complications.  
Hospitalization  18 per 1,000  
7 per 1,000 
(2 to 28)  
RR 0.38 
(0.09 to 1.61)  
685 
(3 RCTs)  
⨁◯◯◯ 
VERY LOW a,b 
Transperineal biopsy probably results 
in little to no difference in 
hospitalization.  
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of 
the intervention (and its 95% CI).  
 
CI: Confidence interval; RR: Risk ratio  
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a 
possibility that it is substantially different 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect  
 
Explanations 
a. Risk of bias for random sequence generation, blinding, allocation concealment high/unclear in a number of included RCTs  







Supplementary Appendix 5 GRADE_R1
Intervention 2  
 
Summary of findings:  
Standard compared to extended number of biopsy cores for prevention of infectious complications 
following prostate biopsy 
Patient or population: Prevention of infectious complications following prostate biopsy  
Setting: Patients undergoing prostate biopsy 
Intervention: Standard number of biopsy cores 
Comparison: Extended number of biopsy cores 
Outcomes 
Anticipated absolute effects* 
(95% CI)  
Relative effect 




Certainty of the 
evidence 
(GRADE)  









43 per 1,000  
34 per 1,000 
(23 to 52)  RR 0.80 
(0.53 to 1.22)  
2230 
(9 RCTs)  
⨁⨁◯◯ 
LOW a,b 
The evidence suggests that using a 
standard compared to extended 
number of biopsy cores results in little 
to no difference in pooled infectious 
complications.  
Hospitalization  10 per 1,000  
3 per 1,000 
(0 to 21)  RR 0.34 
(0.05 to 2.13)  
826 
(5 RCTs)  
⨁◯◯◯ 
VERY LOW a,c 
A Standard (compared to extended) 
number of biopsy cores probably 
results in little to no difference in 
hospitalization.  
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of 
the intervention (and its 95% CI).  
 
CI: Confidence interval; RR: Risk ratio  
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a 
possibility that it is substantially different 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect  
 
Explanations 
a. Bias for allocation concealment, blinding of participants and outcome assessment mostly high/unclear  
b. 95% CI includes no effect  




Intervention 3  
 
Summary of findings:  
Periprostatic nerve block compared to no periprostatic nerve block for prevention of infectious 
complications following prostate biopsy 
Patient or population: Prevention of infectious complications following prostate biopsy  
Setting: Patients undergoing prostate biopsy 
Intervention: Periprostatic nerve block  
Comparison: No periprostatic nerve block 
Outcomes 
Anticipated absolute effects* 
(95% CI)  
Relative effect 




Certainty of the 
evidence 
(GRADE)  









25 per 1,000  
27 per 1,000 
(19 to 37)  RR 1.07 (0.77 to 1.48)  
5540 
(40 RCTs)  
⨁◯◯◯ 
VERY LOW a,b 
Periprostatic nerve block may result 
in little to no difference in pooled 
infectious complications.  
Hospitalization  12 per 1,000  
14 per 1,000 
(7 to 26)  RR 1.13 
(0.59 to 2.16)  
2199 
(14 RCTs)  
⨁◯◯◯ 
VERY LOW a,b 
The evidence suggests that 
periprostatic nerve block results in 
little to no difference in 
hospitalization.  
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of 
the intervention (and its 95% CI).  
 
CI: Confidence interval; RR: Risk ratio  
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a 
possibility that it is substantially different 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect  
Explanations 
a. Risk of bias for allocation concealment, blinding and random sequence generation unclear/high across most studies  














Summary of findings:  
Standard compared to extended number of injections for periprostatic nerve block for prevention of 
infectious complications following prostate biopsy 
Patient or population: Prevention of infectious complications following prostate biopsy  
Setting: Patients undergoing prostate biopsy 
Intervention: Standard number of injections for periprostatic nerve block 
Comparison: Extended number of injections for periprostatic nerve block 
Outcomes 
Anticipated absolute effects* 
(95% CI)  
Relative effect 



















9 per 1,000  
11 per 1,000 
(3 to 41)  RR 1.30 
(0.35 to 4.76)  
927 
(6 RCTs)  
⨁⨁◯◯ 
LOW a,b 
Standard number of injections 
(compared to extended) may result in 
little to no difference in pooled 
infectious complications.  
Hospitalization  13 per 1,000  
14 per 1,000 
(2 to 96)  
RR 1.05 
(0.15 to 7.32)  
300 
(2 RCTs)  
⨁⨁◯◯ 
LOW a,b 
Standard number of injections 
(compared to extended) may result in 
little to no difference in hospitalization  
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of 
the intervention (and its 95% CI).  
 
CI: Confidence interval; RR: Risk ratio  
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a 
possibility that it is substantially different 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect  
Explanations 
a. High and unclear risk of bias for blinding of participant, allocation concealment, outcomes  











Summary of findings:  
Disposable needle guide compared to reusable needle guide for prevention of infectious complications 
following prostate biopsy 
Patient or population: Prevention of infectious complications following prostate biopsy  
Setting: Patients undergoing prostate biopsy 
Intervention: Disposable needle guide  
Comparison: Reusable needle guide 
Outcomes 
Anticipated absolute effects* 
(95% CI)  
Relative effect 




Certainty of the 
evidence 
(GRADE)  









157 per 1,000  
80 per 1,000 
(38 to 167)  RR 0.51 (0.24 to 1.06)  
253 
(2 RCTs)  
⨁◯◯◯ 
VERY LOW a,b 
Disposable needle guide may result 
in little to no difference in pooled 
infectious complications.  
Hospitalization  64 per 1,000  
35 per 1,000 
(11 to 112)  RR 0.55 
(0.17 to 1.74)  
253 
(2 RCTs)  
⨁◯◯◯ 
VERY LOW a,b 
The evidence suggests that 
disposable needle guide results in 
little to no difference in 
hospitalization.  
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of 
the intervention (and its 95% CI).  
 
CI: Confidence interval; RR: Risk ratio  
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a 
possibility that it is substantially different 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect  
Explanations 
a. Bias for random sequence generation, blinding of participants, blinding of outcome assessment high or unclear in one of 2 studies  










Intervention 6  
 
No GRADE analysis performed, because no meta-analysis possible.  
 
Intervention 7  
 
No GRADE analysis performed, because no meta-analysis possible.  
 
 
Intervention 8  
 
 
Summary of findings:  
Enema compared to no enema for prevention of infectious complications following prostate biopsy 
Patient or population: Prevention of infectious complications following prostate biopsy  
Setting: Patients undergoing prostate biopsy 
Intervention: Rectal preparation with enema  
Comparison: Rectal preparation without enema  
Outcomes 
Anticipated absolute effects* 
(95% CI)  Relative effect 















93 per 1,000  
89 per 1,000 
(56 to 142)  RR 0.96 (0.60 to 1.53)  
671 
(4 RCTs)  
⨁⨁◯◯ 
LOW a,b 
Enema may result in little to no 
difference in pooled infectious 
complications.  
Hospitalization  35 per 1,000  
39 per 1,000 
(15 to 99)  
RR 1.13 
(0.44 to 2.86)  
462 
(2 RCTs)  
⨁⨁◯◯ 
LOW a,b 
The evidence suggests that enema 
results in little to no difference in 
hospitalization.  
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of 
the intervention (and its 95% CI).  
 
CI: Confidence interval; RR: Risk ratio  
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a 
possibility that it is substantially different 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect  
Explanations 
a. Bias for Blinding of participants, Blinding of outcome assessment, Allocation concealment and random sequence generation was mostly high or unclear in 
included RCTs  










Summary of findings:  
Povidone-iodine rectal preparation compared to no povidone-iodine rectal preparation for prevention of 
infectious complications following prostate biopsy 
Patient or population: Prevention of infectious complications following prostate biopsy  
Setting: Patients undergoing prostate biopsy 
Intervention: Rectal preparation with povidone-iodine  
Comparison: Rectal preparation without povidone-iodine 
Outcomes 
Anticipated absolute effects* 
(95% CI)  
Relative effect 
















complications  150 per 1,000  
75 per 1,000 
(57 to 99)  
RR 0.50 
(0.38 to 0.65)  
1686 
(8 RCTs)  
⨁⨁◯◯ 
LOW a 
Povidone-iodine rectal preparation 
likely results in a reduction in pooled 
infectious complications.  
Hospitalization  110 per 1,000  
42 per 1,000 
(26 to 93)  
RR 0.38 
(0.21 to 0.69)  
620 
(4 RCTs)  
⨁⨁◯◯ 
LOW a,b 
Povidone-iodine rectal preparation 
probably reduces hospitalization.  
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of 
the intervention (and its 95% CI).  
 
CI: Confidence interval; RR: Risk ratio  
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a 
possibility that it is substantially different 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect  
Explanations 




Supplementary Figure 1 – Comparison of transperineal to transrectal biopsy on 
hospitalization following prostate biopsy. CI = confidence interval; df = degrees of freedom. 
 
 
Supplementary Figure 2 – Comparison of standard to extended biopsy cores on 





Supplementary Figure 3 – Effect of periprostatic nerve block on hospitalization following 
prostate biopsy. CI = confidence interval; df = degrees of freedom. 
 
 
Supplementary Figure 4 – Impact of number of injections for periprostatic nerve block on 




Supplementary Figure 5 – Impact of number of injections for periprostatic nerve block on 
hospitalization following prostate biopsy. CI = confidence interval; df = degrees of freedom. 
 
 
Supplementary Figure 6 – Impact of disposable needle guides on infections complications 
following prostate biopsy. CI = confidence interval; df = degrees of freedom. 
 
 
Supplementary Figure 7 – Impact of disposable needle guides on hospitalization following 




Supplementary Figure 8 – Effect of rectal preparation with enema on hospitalization 
following prostate biopsy. CI = confidence interval; df = degrees of freedom. 




























































Abughosh, 2013 X X X X 
 
      
Adamakis, 2004   X X X     X   
Akan, 2009 X     X 
 
      
Aktoz, 2010 X   X X     X   
Alavi, 2001   Xa   X 
 
  X   
Atta, 2018       Xb     X   
Babaei Jandaghi, 2016 X     X     X   
Bas, 2019    X     
Basar, 2005 X     X 
 
      
Bingqian, 2009 X     X     X   
Bolat, 2016 Xc     X 
 
  X   
Bolat, 2019 X     X     X   
Brown, 1981 X       X X     
Cadilhe, 2017       X 
 
      
Cerruto, 2014 X     X 
 
      
Cevik, 2006 X   X X         
Chae, 2009   X X X     X   
Cormio, 2012 X     X         
Costa, 2019 X   X X   X     
De Nunzio, 2015     Xd       Xd   
Emiliozzi, 2004 X     X 
 
  X   
Ergani, 2020  Xa X X   X  
Ghafoori, 2012   X X X     X X 
Giannarini, 2009     X X 
 
      
Guo, 2015 X   X X     X   
Gurbuz, 2010     X X 
 
  X   
Gurbuz, 2011 X X   X X X X   
Hara, 2006 X   X         X 
Herrera-Caceres, 2015 X X   X 
 
X X   
Hetta, 2014 X Xa   X         
Hiros, 2010 X     X 
 
      
Inal, 2003     X X         
Supplementary Table 1 Infection outcomes reported_R1
Inal, 2004     X X         
Inal, 2008 X     X         
Irani, 2013 X Xa   X         
Izol, 2012       Xe         
Jindal, 2015 X   X X     X   
Jones, 2003       Xf         
Kang, 2012       Xf 
 
      
Kanjanawongdeengam, 2009 X X X X X   X   
Kim, 2011   Xa   X 
 
  X   
Kim, 2019 X   X X 
 
      
Klein, 2010   Xa   X         
Knobloch, 2002   Xa   X         
Koc, 2010 X X   X   X X   
Kravchick, 2005   Xc   X         
Kucur, 2015   Xa   X         
Kuppusamy, 2010     X X         
Lecuona, 2011 X     X         
Li, 2009 X   X X         
Lindert, 2000 X     X X X     
Liu, 2009 X     X 
 
      
Mallick, 2005 X     X         
Mariappan, 2004 X     X 
 
      
Mazdak, 2018 X   X X     X   
Medina Marquez, 2006         X       
Melekos, 1990 X     X X X     
Naughton, 2000 X     X     X   
Novella, 2003 X X   X         
Obek, 2002 X     X   X X   
Ould Ismail, 2012   Xa   X     X   
Ozden, 2003 X     X 
 
  X   
Park, 2005 X X   X         
Paul, 2004 X     X 
 
  X   
Pontes, 2017   Xa   X         
Ragavan, 2005 X     X     X   
Rodríguez-Covarrubias, 2011 X     X     X   
Ryu, 2019 X     X         
Salomon, 2019 X X        X   
Sataa, 2010   Xa   X         
Seymour, 2001 X     X     X   
Sharpe, 1982 X     X 
 
X     
Singh, 2017 X     X   X     
Song, 2006   X   X 
 
  X   
Su, 2019   X   X 
 
  X   
Sur, 2004   Xa X X         
Szlauer, 2008   Xa   X         
Taher, 2014       Xf         
Tekdogan, 2006 X X   X   X     
Tobias Machado, 2002 X Xa   X         
Tobias-Machado, 2006   X   X         
Toi, 2012     X X         
Trucchi, 2005   Xa X X         
Tuncel, 2008 X X   X X X X   
Udeh, 2015 X     X 
 
      
Wang, 2016 X     X         
Wegelin, 2019 X X   X 
 
  X   
Xu, 2012 X     X         
Xu, 2014 X     X         
Yu, 2014   X   X 
 
      

















bminor and major infectious complications 
cfebrile UTI 




Supplementary table 2 - Characteristics of excluded studies 
Study Reason for exclusion 
Abboud, 2015 No RCT, but non-randomized trial 
Abughosh, 2011 Partial publication (abstract only), fulltext included (Abughosh 2013) 
Abughosh, 2012 Partial publication (abstract only), fulltext included (Abughosh 2013) 
Abughosh, 2012 Partial publication (abstract only), fulltext included (Abughosh 2013) 
Addla, 2003 Periprostatic injection in all groups 
Akay, 2006 Inadequate randomization by order of the arrival 
Akdeniz, 2018 Periprostatic injection in all groups 
Akdere, 2013 No infective outcome reported 
Akpinar, 2009 Periprostatic injection in all groups 
Alabi, 2018 Inadequate randomization by alternationa 
Alam, 2017 No infective outcome reported 
Alberts, 2017 No infective outcome reported 
Alireza, 2012 No infective outcome reported 
Allen, 2017 No RCT, but non-randomized trial 
Ananth, 2000 No RCT, but study comment 
Anastasi, 2016 No infective outcome reported 
Anup, 2013 Periprostatic injection in all groups 
Arguelles Salido, 2008 No detailed raw data on infective complications availablea 
Arsov, 2015 No infective outcome reported 
Arsov, 2015 Interfering second intervention (antibiotics) 
Arsov, 2016 Interfering second intervention (antibiotics) 
Ashley, 2007 No infective outcome reported 
Avci, 2012 No infective outcome reported 
Baco E, 2016 No infective outcome reported 
Barbosa, 2010 No clear evidence for RCT, no feedback from authors recieved 
Barry Delongchamps, 2013 No RCT, but uncontrolled trial 
Berger, 2003 Periprostatic injection in all groups 
Bidnur, 2016 No RCT, but study comment 
Black, 2011 No clear raw data on infectious complications 
Boehm, 2017 Partial publication (abstract only), fulltext included (Salomon 2018) 
Bozlu, 2004 Periprostatic injection in all groups 
Buckley, 2006 Inadequate randomization by alternation of week 
Cam, 2008 Periprostatic injection in all groups 
Cantiello, 2012 Periprostatic injection in all groups 
Cengiz, 2013 No infective outcome reported 
Cermak, 2009 No infective outcome reported 
Cermak, 2010 No RCT, but retrospective data analysis of a uncontrolled trial 
Cerruto, 2010 Partial publication (abstract only), fulltext included (Cerruto 2014) 
Chen, 2018 No RCT, but retrospective data analysis of a controlled trial 
Chen, 2018 No RCT, but retrospective data analysis of a controlled trial 
Cheng, 2018 No infective outcome reported 
Chi, 2011 No RCT, but non-randomized controlled trial 
Ching, 2009 No RCT, but non-randomized observational study 
Cicione, 2012 No infective outcome reported 
Supplementary Table 2 Excluded RCTs_R1
Cicione, 2013 No infective outcome reported 
Conde Redondo, 2006 No clear raw data on infectious complications, no feedback from authors recieved 
Cormio, 2010 No clear raw data on infectious complications 
Cormio, 2011 No infective outcome reported 
Damiano, 2004 No clear raw data on infectious complications, no feedback from authors recieved 
de la Rosette, 2009 No infective outcome reported 
De Nunzio, 2011 Inadequate randomization by alternationa 
Del Campo, 2016 No RCT, but observational study 
D'Elia, 2019 Inadequate randomization by date of birth 
D'Eramo, 2012 Periprostatic injection in all groups 
Ding, 2018 No infective outcome reported 
Durmus, 2013 No RCT, but retrospective data analysis of a controlled trial 
Emiliozzi, 2003 No RCT, but prospective observational study 
Gavazzi, 2009 No RCT, but non-randomized controlled trial 
Ghafoori, 2015 No clear raw data on infectious complications, no feedback from authors recieved 
Ghani, 2004 No RCT, but prospective non-randomized trial 
Giannarini, 2009 No infective outcome reported 
Giannarini, 2009 No infective outcome reported 
Griwan, 2012 No clear raw data on infectious complications 
Guo, 2017 No RCT, but retrospective data analysis 
Haga, 2012 No intervention of interest 
Haggarth, 2002 Periprostatic injection in all groups 
Hamid, 2019 No intervention of interest 
Hara, 2008 Partial publication, Fulltext included (Hara 2006) 
Herranz Amo, 2010 No infective outcome reported 
Ho, 2010 No clear raw data on infectious complications, no feedback from authors recieved 
Horinaga, 2006 No infective outcome reported 
Huang, 2006 No RCT, but retrospective data analysis  
Inal, 2004 No infective outcome reported 
Irani, 2013 Partial publication (abstract only), fulltext included (Irani 2013) 
Ismail, 2015 No infective outcome reported 
Jambor, 2019 No RCT, but prospective non-randomized trial 
Kandirali, 2009 No intervention of interest 
Karman, 2009 No infective outcome reported 
Kato, 2011 No RCT, but non-randomized controlled trial 
Kaufmann, 2018 No RCT, but non-randomized controlled trial 
Kaver, 2002 No infective outcome reported 
Kim, 2004 No infective outcome reported 
Kim, 2010 No infective outcome reported 
Klein, 2009 No RCT, but prospective non-randomized trial 
Koprulu, 2012 No RCT, but non-randomized retrospective and prospective trial 
Kumar, 2012 No infective outcome reported 
Kumar, 2013 Periprostatic injection in all groups 
Kuppusamy, 2009 No infective outcome reported 
Lee, 2007 Periprostatic injection in all groups 
Lee, 2017 Partial publication (abstract only), Fulltext included (Ryu 2019) 
Lee, 2020 Inadequate randomization by alternation of month 
Leibovici, 2002 Periprostatic injection in all groups 
Leitao, 2011 No infective outcome reported 
Li, 2014 No clear evidence for RCT 
Li, 2017 No infective outcome reported 
Lim, 2016 No infective outcome reported 
Lipczynski, 2012 No intervention of interest 
Lorusso, 2010 No infective outcome reported 
Lujan Marco, 2009 Inadequate randomization by alternation of day  
Lunacek A, 2014 No infective outcome reported 
Lunacek, 2013 No infective outcome reported 
Lunacek, 2014 No infective outcome reported 
Lynn, 2002 No infective outcome reported 
Mallick, 2004 Partial publication, fulltext included (Mallick 2005) 
Mallick, 2004 Partial publication in French, fulltext included (Mallick 2005) 
Mamoulakis, 2009 Partial publication (abstract only), fulltext excluded (de la Rosette 2009) 
Mamoulakis, 2009 Partial publication (abstract only), fulltext excluded (de la Rosette 2009) 
Manikandan, 2003 No infective outcome reported 
Matlaga, 2003 No infective outcome reported 
McCormack, 2012 Inadequate randomization by patients chart number (even/odd)a 
McGee, 2015 No RCT, but retrospective data analysis 
Mitterberger M, 2007 No infective outcome reported 
Mitterberger, 2007 No RCT, but all patients recieved both techniques 
Montoliu Garcia A, 2010 No clear raw data on infectious complications, no feedback from authors recieved 
Montoliu Garcia, 2009 Inadequate randomization by number of medical history (even/odd) 
Moreira, 2016 No RCT, but retrospective analysis of a RCT 
Moudouni, 2011 Partial publication (abstract only), fulltext is Moudouni 2014 
Moudouni, 2014 No clear raw data on infectious complications, no feedback from authors recieved 
Nambirajan, 2004 Periprostatic injection in all groups 
Nash, 1996 No infective outcome reported 
Nasu, 2009 No infective outcome reported 
Naughton, 2001 No infective outcome reported 
Nava, 1993 No RCT, but non-randomized controlled trial 
Nguyen, 2007 No infective outcome reported 
Noh, 2010 Periprostatic injection in all groups 
Nour, 2009 No clear raw data on infectious complications 
Nouri, 2010 No infective outcome reported 
Novac, 2013 No infective outcome reported 
Obek, 2004 Interfering second intervention (antibiotics) 
Obi, 2011 No infective outcome reported 
Obi, 2015 No infective outcome reported 
Ortegren, 2019 No RCT, but retrospective data analysis of infections 
Ozcan, 2017 No clear evidence for RCT, no feedback from authors recieved 
Ozok, 2010 Periprostatic injection in all groups 
Ozveri H, 2003 No clear evidence for RCT, no feedback from authors recieved 
Paffen, 2015 No clear evidence for RCT 
Park, 2009 No RCT, but non-randomized controlled trial 
Park, 2010 No clear raw data, no feedback from authors recieved 
Pathak, 2015 No infective outcome reported 
Pathak, 2017 No infective outcome reported 
Paul, 2005 Partial publication, complete study published under Paul 2004 
Pepe, 2017 No RCT, all patients recieved both interventions 
Porpiglia, 2016 Interfering second intervention (antibiotics) 
Qu, 2016 No RCT, but non-randomized controlled trial 
Raber, 2008 Interfering second intervention (antibiotics) 
Raber, 2011 No infective outcome reported 
Rabets, 2004 No infective outcome reported 
Raman, 2015 No RCT, but non-randomized prospective trial 
Raman, 2015 No RCT, but description of rectal preparation with povidone-iodine 
Robins, 2017 No infective outcome reported 
Robins, 2018 No RCT, but non-randomized controlled trial 
Rochester, 2009 No infective outcome reported 
Rodriguez, 2002 No infective outcome reported 
Rodriguez, 2003 No infective outcome reported 
Rohit, 2019 No infective outcome reported 
Saha, 2014 No infective outcome reported 
Sahin, 2015 No infective outcome reported 
Salido, 2008 No clear raw data on infectious complications 
Salomon, 2017 Partial publication (abstract only), fulltext included (Salomon 2018) 
Salomon, 2018 Double publication, fulltext included (Salomon 2018) 
Saredi, 2009 No clear raw data on infectious complications, no feedback from authors recieved 
Saredi, 2010 No clear raw data on infectious complications, no feedback from authors recieved 
Sarmiento, 2018 No clear evidence for RCT 
Schostak, 2002 No infective outcome reported 
Sekiner, 2011 Periprostatic injection in all groups 
Sen, 2015 Periprostatic injection in all groups 
Siddiqui, 2006 No RCT, but non-randomized controlled trial 
Singh, 2011 No infective outcome reported 
Singh, 2012 Periprostatic injection in all groups 
Song, 2004 Double publication in Korean, English publication included (Song 2006) 
Sridhar, 2020 No clear raw data on infectious complications 
Stamatiou, 2007 No clear evidence for RCT 
Stirling, 2002 No infective outcome reported 
Stirling, 2002 No infective outcome reported 
Stravodimos, 2007 No infective outcome reported 
Taher, 2015 Double publication (abstract only), Taher 2014 (abstract only) included 
Takenaka, 2008 Partial publication, Fulltext included (Hara 2006) 
Tas, 2005 Double publication (Inal 2008) 
Taverna, 2011 No infective outcome reported 
Turgut At, 2006 No infective outcome reported 
Turgut, 2006 No infective outcome reported 
Valero Sarmiento, 2018 No clear evidence for RCT 
van der Leest, 2019 No intervention of interest 
Walker, 2002 Periprostatic injection in all groups 
Walsh, 2004 No infective outcome reported 
Wang, 2019 No clear evidence for RCT 
Wegelin, 2019 Double publication, fulltext included (Wegelin 2019) 
Woolsey S, 2002 Periprostatic injection in all groups 
Wu, 2001 No infective outcome reported 
Yang, 2009 No infective outcome reported 
Yildirim, 2015 No RCT, but retrospective data analysis of a non-randomized controlled trial 
Yun, 2007 Periprostatic injection in all groups 
Yurdakul, 2009 No infective outcome reported 
Zare, 2012 No clear evidence for RCT 
ainformation provided by authors 
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roup 1) 40 patients received 10 m
l ultrasound gel intrarectally 10 m








roup 2) 78 patients received 10 m
l EM
LA
 intrarectally 10 m


















Extended nerve block 
G
roup 1) 60 patients received periprostatic nerve block w
ith 2 injections of 5 m
L 1%
 
lidocaine basal 5 m








roup 2) 57 patients received periprostatic nerve block w
ith 5 m
L of 1%
 lidocaine at the 
apex 5 m










roup 1) 30 patients received 50 m
g diclofenac sodium
 suppository 30 m








roup 2) 30 patients received 3.3 m
l of 0.75%
 levobupivacaine as bilateral periprostatic 








roup 3) 30 patients received 50 m
g diclofenac 30 m
in before biopsy plus 3.3 m
l of 0.75%
 















bilaterally at the prostate base 3 m








roup 2) 75 patients received 10 m
l 2%
 lidocaine gel intrarectally 10 m






















roup 2) 100 patients underw













roup 3) 100 patients received i.v. sedation w
ith diazepam
 5 m




 lidocaine 3-5 m
in before biopsy. 
  
B
abaei Jandaghi, 2016 
Iran 
English 




roup 1) 125 patients transperineal biopsy w
ith a coaxial Tru-C








roup 2) 125 patients transperineal biopsy w











roup 1) 60 patients underw










roup 2) 32 patients underw












roup 1) 20 patients received ultrasound gel intrarectally15 m








roup 2) 20 patients received 1g EM
LA
 cream
 intrarectally 15 m








roup 3) 20 patients underw
ent periprostatic nerve block w
ith 6 m
l 1%
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roup 4) 20 patients underw
ent periprostatic nerve block w
ith 6 m
l 1%













roup 1) 100 patients underw

















roup 2) 100 patients underw





























roup 1) 198 patients underw











roup 2) 178 patients underw
ent intrarectal 10 m
l 2%



















roup 1) 73 patients underw










roup 2) 65 patients underw
ent intrarectal 60 m









 prilocaine and 5 m
l of 0.25 bupivacaine m
ixture 5 m








1978 - 1979 
Povidone-iodine 
G


































roup 4) 11 patients 50 m
l 10%








2014 - 2016 
Povidone-iodine 
G
roup 1) 47 patients rectal preparation w
ith 2,5 m










roup 2) 47 patients w










roup 1) 54 patients received transperineal biopsy w













roup 2) 54 patients received transrectal biopsy w
ith 14 cores under periprostatic nerve 
block using 1%








2003 - 2005 
Extended nerve block 
G
roup 1) 60 patients underw













roup 2) 60 patients underw





l on each side basal side) and 2 m
l (1 m












roup 1) 100 patients underw








roup 2) 100 patients underw











roup 1) 100 patients received 5 g 2.5%




solution gel 1 h before biopsy follow
ed by 5 g 2.5%














roup 2) 100 patients received 5 g 2.5%






















roup 1) 401 patients underw
ent rectal cleansing w
ith povidone-iodine plus form
alin 








roup 2) 401 patients served as control w













roup 1) 97 patients received enem








roup 2) 101 patients received bow
el preparation w
ith 34.8 g/4L polyethylene glycol-
electrolyte solution (PEG










roup 1) 107 patients w








roup 2) 107 patients w








roup 1) 101 patients received no rectal preparation w
ith 2%























roup 3) 50 patients received rectal preparation w
ith 10%










2009 - 2010 
Povidone-iodine 
G
roup 1) 140 patients 50 g of lidocaine 2%
 gel w
ith 20 m









roup 2) 140 patients 50 g of lidocaine 2%










roup 1) 68 patients received intrarectal 5 g lidocaine-prilocaine cream




l per side) as periprostatic nerve block 5 m



















roup 3) 68 patients received 10 m
l 1%
 lidocaine (5 m
l per side) as periprostatic nerve 
block 5 m








roup 4) 67 patients received intrarectal lubricant gel 30 m











roup 1) 173 patients received transperineal biopsy w
ith 8 cores (prostate volum
e < 50m
l) 
or 12 cores (prostate volum
e >50 m












roup 2) 166 patients received transrectal biopsy w
ith 8 cores (prostate volum
e < 50m
l) or 
12 cores (prostate volum
e >50 m









2008 - 2009 
  
G
roup 1) 25 patients w








roup 2) 25 patients received 5 m
l 1%
 lidocaine as injection at the 3 o clock and 9 o clock 








roup 3) 25 patients underw
ent periprostatic nerve block w
ith 10 m
l (5 m
l per side) 1%
 








roup 4) 25 patients received intrarectal 5 m













roup 1) 25 patients transrectal 10 core biopsy w








roup 2) 30 patients transrectal 10 core biopsy w










roup 1) 168 patients received transperineal biopsy w








roup 2) 174 patients received transrectal biopsy w


































roup 1) 25 patients received periprostatic nerve block w
ith 5 m























roup 1) 30 patients received 4 periprostatic injections of 2,5 m
l of 1%
 lidocaine as 
















roup 3) 30 patients received 20 m









roup 1) 25 patients received periprostatic nerve block w
ith 3 m
l 1%







































roup 3) 20 patients received periprostatic nerve block w
ith 6 m
l 1%
 lidocaine (3 m
l per 
side) 5 m










roup 1) 103 patients received biopsy w









roup 2) 101 patients received biopsy w










roup 1) 158 patients w








roup 2) 148 patients w

















roup 2) 25 patients received periprostatic nerve block w
ith 5 m
l 2%









roup 3) 25 patients received local anesthesia w
ith 10 m
l 2%























roup 1) 47 patients received Intrarectal local anaesthesia w
ith 10 m
l 2%
 lignocaine jelly 
and underw
ent pelvic plexus block w
ith 2.5 m
l 2%








roup 2) 46 patients received Intrarectal local anaesthesia w
ith 10 m
l 2%
 lignocaine jelly 
and periprostatic nerve block w
ith 2,5 m
l of 2%
























roup 1) 30 patients received periprostatic nerve block w
ith 10 m
l lidocaine (5 m




















roup 1) 31 patients received 10 m
l 2%








roup 2) 30 patients received periprostatic nerve block w
ith 10 m
l 1%
 lidocaine after local 
application of 10 m
l 2%
 lidocaine gel 5 m








roup 3) 31 patients received periprostatic nerve block w
ith 20 m
l 1%
 lidocaine after local 
application of 10 m
l 2%
 lidocaine gel 5 m









2008 - 2009 
Povidone-iodine 
G









roup 2) 50 patients received enem
a and gauze soaked w
ith l0%















roup 1) 125 patients underw
ent periprostatic nerve block w
ith 1%

































roup 1) 55 patients underw
ent intrarectal local anesthesia w
ith 10 m
l of 2%
 lidocaine gel 
plus pelvic plexus block w
ith 3 m
l of 2%








roup 2) 55 patients underw
ent intrarectal local anesthesia w
ith 10 m
l of 2%
 lidocaine gel 
plus periprostatic nerve block w
ith 3 m
l of 2%









roup 3) 53 patients underw
ent intrarectal local anesthesia w
ith 10 m
l of 2%












roup 1) 74 patients received 2%
 lidocaine gel 15 m









roup 2) 71 patients underw
ent periprostatic nerve block w
ith 10 m
l 2%
 prilocaine (5 m
l 
per side) plus 2%
 lidocaine gel 15 m












roup 1) 34 patients underw
ent periprostatic nerve block w
ith 5-10 m
l 1%
 articaine (5 m
l 
per side) 2-3 m
in before biopsy and received 6 m
l 2%









roup 2) 34 patients received 6 m
l 2%











roup 1) 84 patients transrectal 12 core biopsy w
ith biopsy needle disinfection w
ith 10%
 








roup 2) 96 patients transrectal 12 core biopsy w











roup 1) 28 patients received 10 m
l of 2%
 lidocaine gel intrarectal 10 m
















 lidocaine gel 
intrarectal 10 m








roup 3) 29 patients received 10 m
l perianal injection of 1%
 lidocaine 2 m









roup 4) 27 patients received periprostatic nerve block w
ith 5 m
l 1%











roup 1) 50 patients received 10 m
l of 2%
 lidocaine gel intrarectal and underw
ent 5 
m
inutes later a prostatic nerve block w
ith 2.5 m
l of 2%








roup 2) 50 patients received low
 dose spinal anesthesia by injecting 0.3 m
l, 0.5%
 
hyperbaric bupivacaine into the spinal subarachnoid space betw











 extended nerve 
block 
G








roup 2) 106 patients received periprostatic nerve block w
ith 10 m
l 1%
 lignocaine in one 
apical injection 10 m








roup 3) 87 patients received periprostatic nerve block w
ith 5 m
l 1%
 lignocaine injected on 
both basal sides 10 m








roup 4) 106 patients received periprostatic nerve block w
ith 4 m
l 1%
 lignocaine injected 
in the apex region and 3 m
l 1%
 lignocaine injected in both basal sides 10 m










roup 1)152 patients w
ith num











roup 2) 151 patients w












roup 1) 60 patients recieved periprostatic nerve block w
ith 10 m
l 2%
 lidocaine injection 
(5 m
































































roup 2) 30 patients underw
ent periprostatic nerve block w
ith 5 m
l 1%
 lidocaine injection 
per side 5 m








roup 3) 30 patients received intrarectal lidocaine gel and underw
ent 5 m
in later a 
periprostatic nerve block w
ith 5 m
l 1%
 lidocaine injection per side 5 m








roup 4) 30 patients received 2 m
l 1%
 lidocaine injection on both prostatic lobes and 
thereafter a periprostatic nerve block w
ith 5 m
l 1%













roup 1) 180 patients received 15 m
l 2%
 lidocaine gel intrarectally 10 m








roup 2) 176 patients underw





l per side) 4 m











roup 1) 69 patients underw








roup 2) 63 patients underw










roup 1) 36 patients underw
ent local anesthesia w
ith intrarectal application of 10 m
l 











roup 2) 35 patients underw











roup 3) 35 patients received general sedation w
ith 25 µg/kg m
idazolam
















roup 1) 22 patients received 10 m
l of 2%





















roup 1) 18 patients received 50 m
l of 5%
 povidone-iodine enem
a (PIE) for 10 m
inutes 


















roup 3) 25 patients received 50 m
l of 5%
 povidone-iodine enem
a (PIE) for 10 m
inutes 




















roup 1) 72 patients w








roup 2) 62 patients w










roup 1) 51 patients underw








roup 2) 51 patients underw











roup 1) 50 patients underw
ent periprostatic nerve block w
ith 2.5 m
l 2%
 lidocaine on each 
side 3 m
















2007 - 2009 
Extended nerve block 
G
roup 1) 90 patients received periprostatic nerve block w
ith 8 m
l 1%
 lidocaine basal 








roup 2) 92 patients received periprostatic nerve block w
ith 8 m
l 1%
 lidocaine basal 
injection on each side and 2 m
l 1%






2001 - 2002 
Extended nerve block 
G
roup 1) 25 patients underw











roup 2) 25 patients underw
ent periprostatic nerve block w
ith a total of 2.5 m
l 1%
 








roup 3) 25 patients underw
ent periprostatic nerve block w
ith a total of 2.5 m
l 1%
 








roup 4) 25 patients underw
ent periprostatic nerve block w
ith a total of 5 m
l 1%
 lidocaine 








roup 5) 25 patients underw
ent periprostatic nerve block w
ith a total of 5 m
l 1%
 lidocaine 








roup 6) 25 patients underw
ent periprostatic nerve block w
ith a total of 10 m
l 1%
 lidocaine 








roup 7) 25 patients underw
ent periprostatic nerve block w
ith a total of 10 m
l 1%
 lidocaine 











roup 1) 19 patients underw
ent periprostatic nerve block w
ith 10 m
l of 1%
 lidocaine on 
bilateral plus intrarectal application of 20 m
l of 2%
 lidocaine gel 10 m








roup 2) 23 patients underw
ent periprostatic nerve block w
ith 10 m
l of 1%









roup 3) 19 patients received intrarectal application of 20 m
l of 2%
 lidocaine gel 10 
m











roup 1) 84 patients w








roup 2) 88 patients w










roup 1) 379 patients w








roup 2) 379 patients w












roup 1) 55 patients underw
ent periprostatic nerve block w
ith 10 m
l 1%
 lidocaine injection 
basal at each side som
e m








roup 2) 55 patients received a 100 m
g diclofenac suppository 40 m
in before biopsy and 
periprostatic nerve block w
ith 10 m
l 1%











roup 3) 55 patients received 100 m
g diclofenac suppository 40 m













roup 1) 75 patients w








roup 2) 75 patients w







2014 - 2016 
Povidone-iodine 
G
roup 1) 120 patients received a 200 m
g povidone-iodine suppository w
hich w
as inserted 1 




















roup 1) 494 patients received an antim














roup 2) 506 patients received the standard non-antim









roup 1) 33 patients received 10 m
l 2%








roup 2) 33 patients underw
ent periprostatic nerve block w
ith 10 m
l 1%
 lidocaine injection 
apical 10 m








roup 3) 34 patients received 10 m












roup 1) 84 patients underw
ent periprostatic nerve block w
ith 5 m
l 2%
 lignocaine injection 
on each side of the apex 2 m

















roup 1) 40 patients cleansing enem
a night before and 20 m









roup 2) 40 patients cleansing enem
a night before and 20 m









roup 1) 60 patients received transperineal biopsy w








roup 2) 60 patients received transrectal biopsy w










roup 1) 30 patients received each 20 m
l 2%
 lidocine gel intarectally 10 m








roup 2) 30 patients underw




injection basal on each side 10 m








roup 3) 30 patients underw
ent periprostatic injection w
ith 2.5 m
l norm
al saline on each 
side 10 m










roup 1) 140 patients received levofloxacin 500 m











roup 2) 140 patients received levofloxacin 500 m










roup 3) 140 patients received levofloxacin 500 m
g p.o. starting 1 h before biopsy for a 












roup 1) 88 patients w








roup 2) 94 patients w










roup 1) 25 patients received a suppository containing 60 m








roup 2) 25 patients received a suppository containing 120 m








roup 3) 25 patients received a suppository containing 120 m








roup 4) 25 patients underw
ent periprostatic nerve block w
ith 5 m
l 2%











roup 1) 60 patients received perineal cleansing w








roup 2) 60 patients w









roup 1) 39 patients received ciprofloxacin 1000 m
g p.o. per day starting the evening 








roup 2) 40 patients received ciprofloxacin 1000 m
g p.o. per day starting the evening 

































roup 1) 20 patients underw
ent periprostatic nerve block w
ith 2.5 m
l of 1%









roup 2) 20 patients underw











roup 1) 20 patients received 20 m
l of 2%
 lidocaine gel intrarectal 10 m








roup 2) 60 patients underw
ent periprostatic nerve block w
ith 2.5 m
l of 1%









roup 3) 60 patients received 20 m







g i.v. 10 m








roup 4) 20 patients received 15 m







Extended nerve block 
G
roup 1) 89 patients underw
ent periprostatic nerve block w
ith 10 m
l of 1%
 lidocaine into 
the base (5 m








roup 2) 89 patients underw
ent periprostatic nerve block w
ith 10 m
l of 1%
 lidocaine into 
the base (3 m
l per side) and apex (2 m

















roup 2) 20 patients received 10 m
l 1%
 lidocaine gel intrarectal 10 m








roup 3) 20 patients underw















roup 1) 110 patients transrectal 10 core biopsy w








roup 2) 88 patients transrectal 10 core biopsy w











roup 1) 45 patients received transperineal biopsy w








roup 2) 30 patients received transrectal biopsy w











roup 1) 95 patients received 20 m
l 1.2%
 lidocaine as caudal block 5 m








roup 2) 95 patients received 10 m
l 0.3%
 oxybuprocaine gel perianal and underw
ent 
periprostatic nerve block w
ith 5 m
l of a m
ixture of 1%
 lidocaine and 0.5%














roup 1) 77 patients recieved transrectal in-bore M
R








roup 2) 79 patients recieved transperineal M
R









roup 3) 78 patients recieved transrectal cognitive TR
U












roup 1) 60 patients underw








roup 2) 60 patients underw











roup 1) 62 patients underw
ent periprostatic nerve block w
ith 5 m
l of 2%
 lidocaine on 
each side 10 m






















roup 3) 62 patients received intra-m
uscular injection w
ith saline 30 m












roup 1) 66 patients received rectal desinfection w









roup 2) 66 patients received rectal desinfection w









roup 3) 65 patients received rectal desinfection w
ith a iodophor cotton ball before and 
after prostate biopsy 
  
 
